<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">Front Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Front Psychiatry</journal-id>
<journal-id journal-id-type="publisher-id">Front. Psychiatry</journal-id>
<journal-title-group>
<journal-title>Frontiers in Psychiatry</journal-title>
</journal-title-group>
<issn pub-type="epub">1664-0640</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">32256400</article-id>
<article-id pub-id-type="pmc">7093583</article-id>
<article-id pub-id-type="doi">10.3389/fpsyt.2020.00151</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Psychiatry</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Analysis of the Deleterious Single-Nucleotide Polymorphisms Associated With Antidepressant Efficacy in Major Depressive Disorder</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Xin</surname>
<given-names>Juncai</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yuan</surname>
<given-names>Meng</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Peng</surname>
<given-names>Yonglin</given-names>
</name>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Ju</given-names>
</name>
<xref ref-type="corresp" rid="c001">
<sup>*</sup>
</xref>
<uri xlink:href="http://loop.frontiersin.org/people/14299/overview" xlink:type="simple"></uri>
</contrib>
</contrib-group>
<aff><institution>School of Biomedical Engineering, Tianjin Medical University</institution>, <addr-line>Tianjin</addr-line>, <country>China</country></aff>
<author-notes>
<fn fn-type="edited-by">
<p>Edited by: Chad A. Bousman, University of Calgary, Canada</p>
</fn>
<fn fn-type="edited-by">
<p>Reviewed by: Yaowaluck Hongkaew, Mahidol University, Thailand; Neven Henigsberg, University of Zagreb School of Medicine, Croatia</p>
</fn>
<corresp id="c001">*Correspondence: Ju Wang <email>wangju@tmu.edu.cn</email></corresp>
<fn fn-type="other" id="fn001">
<p>This article was submitted to Molecular Psychiatry, a section of the journal Frontiers in Psychiatry</p>
</fn>
</author-notes>
<pub-date pub-type="epub">
<day>18</day>
<month>3</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="collection">
<year>2020</year>
</pub-date>
<volume>11</volume>
<elocation-id>151</elocation-id>
<history>
<date date-type="received">
<day>22</day>
<month>11</month>
<year>2019</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>2</month>
<year>2020</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright © 2020 Xin, Yuan, Peng and Wang.</copyright-statement>
<copyright-year>2020</copyright-year>
<copyright-holder>Xin, Yuan, Peng and Wang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p>
</license>
</permissions>
<abstract>
<p>Major depressive disorder (MDD) is a serious mental disease with negative effects on both mental and physical health of the patient. Currently, antidepressants are among the major ways to ease or treat MDD. However, the existing antidepressants have limited efficacy in treating MDD, with a large fraction of patients either responding inadequately or differently to antidepressants during the treatment. Pharmacogenetics studies have found that the genetic features of some genes are associated with the antidepressant efficacy. In order to obtain a better understanding on the relationship between the genetic factors and antidepressant treatment response, we compiled a list of 233 single-nucleotide polymorphisms (SNPs) significantly associated with the antidepressant efficacy in treating MDD. Of the 13 non-synonymous SNPs in the list, three (rs1065852, rs3810651, and rs117986340) may influence the structures and function of the corresponding proteins. Besides, the influence of rs1065852 on the structure of CYP2D6 was further investigated via molecular dynamics simulations. Our results showed that compared to the native CYP2D6 the flexibility of the F-G loop was reduced in the mutant. As a portion of the substrate access channel, the lower flexibility of F-G loop may reduce the ability of the substrates to enter the channel, which may be the reason for the lower enzyme activity of mutant. This study may help us to understand the impact of genetic variation on antidepressant efficacy and provide clues for developing new antidepressants.</p>
</abstract>
<kwd-group>
<kwd>major depressive disorder</kwd>
<kwd>antidepressants</kwd>
<kwd>non-synonymous SNPs</kwd>
<kwd>protein structure</kwd>
<kwd>molecular dynamics simulations</kwd>
</kwd-group>
<counts>
<fig-count count="6"></fig-count>
<table-count count="4"></table-count>
<equation-count count="0"></equation-count>
<ref-count count="78"></ref-count>
<page-count count="11"></page-count>
<word-count count="7718"></word-count>
</counts>
</article-meta>
</front>
<body>
<sec id="s1" sec-type="intro">
<title>Introduction</title>
<p>Major depressive disorder (MDD) is a serious mental disorder that influences ~6% population worldwide (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B2">2</xref>). The lifetime incidence of depression is ~16.6% (<xref ref-type="bibr" rid="B3">3</xref>, <xref ref-type="bibr" rid="B4">4</xref>), and the rate for females is twice that of males (<xref ref-type="bibr" rid="B5">5</xref>). The symptoms of MDD are complicated, including anxiety, cognitive impairment, suicidal tendencies, and emotional, somatic, and functional impairments (<xref ref-type="bibr" rid="B6">6</xref>). The disease can negatively affect almost all aspects of a person, including personal life, work life, and education, as well as general health. It does not only severely limit the psychosocial functioning and deteriorate life quality of the patients, but also brings heavy spiritual and economic burden to their families and the society (<xref ref-type="bibr" rid="B7">7</xref>). Actually, MDD is among the most burdensome disease worldwide (<xref ref-type="bibr" rid="B8">8</xref>, <xref ref-type="bibr" rid="B9">9</xref>), both in the developed and developing countries (<xref ref-type="bibr" rid="B1">1</xref>, <xref ref-type="bibr" rid="B10">10</xref>, <xref ref-type="bibr" rid="B11">11</xref>), and the World Health Organization predicted that MDD will become the major cause of years lost to disability in 2030 (<xref ref-type="bibr" rid="B12">12</xref>). Thus, it is still a huge challenge to develop more effective therapeutic approaches that can accurately diagnose and treat MDD.</p>
<p>Currently, antidepressants are among the major ways to treat or alleviate MDD. The available antidepressants can be classified into several types according to their structure and the way they work, including selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors, serotonin and norepinephrine reuptake inhibitors, tricyclic antidepressants, and the other antidepressants. However, studies have shown that the existing antidepressants have limited efficacy in treating MDD, and the response of patients to antidepressants is difficult to predict (<xref ref-type="bibr" rid="B13">13</xref>). For example, it is found that the common antidepressants are effective in approximately only 40% of MDD patients (<xref ref-type="bibr" rid="B14">14</xref>), and 30–50% of patients have no response to the initial treatment of antidepressants (<xref ref-type="bibr" rid="B14">14</xref>). Even if a patient responds to an antidepressant, the recurrence rate is usually high (<xref ref-type="bibr" rid="B15">15</xref>).</p>
<p>The biological mechanisms of antidepressant response are still unclear, but earlier studies indicate that genetic factors may play an important part in this procedure (<xref ref-type="bibr" rid="B16">16</xref>–<xref ref-type="bibr" rid="B18">18</xref>). Pharmacogenetic studies show that the genetic characteristics of an individual can make an antidepressant more or less effective, and the single-nucleotide polymorphisms (SNPs) of some genes are related to the drug efficacy (<xref ref-type="bibr" rid="B19">19</xref>). Genes affecting antidepressant efficacy can be roughly grouped into two major categories, that is, genes of cytochrome P450 (CYP) family and those involved in the serotonin biochemical pathway (<xref ref-type="bibr" rid="B20">20</xref>). Members of the CYP family, for example, <italic>CYP2D6, CYP1A2, CYP3A4</italic>, and <italic>CYP2C19</italic>, have been found to play important roles in the metabolism of antidepressants (<xref ref-type="bibr" rid="B19">19</xref>, <xref ref-type="bibr" rid="B21">21</xref>–<xref ref-type="bibr" rid="B23">23</xref>). Because an SNP may lead to abolished, reduced, or increased enzyme activity, some members of CYP families, such as CYP2D6, may have four phenotypes in individuals, including normal metabolizers, intermediate metabolizers, poor metabolizers, and ultrarapid metabolizers (<xref ref-type="bibr" rid="B24">24</xref>). Hence, there is a connection between the <italic>CYP2D6</italic> polymorphisms and the plasma levels of antidepressants; and MDD patients need a dose of antidepressant appropriate to their genetic characteristics to achieve better efficacy and fewer side effects. For genes in the serotonin biochemical pathway, such as the serotonin transporter gene (<italic>SLC6A4</italic>) and 5-hydroxytryptamine receptor 2A (<italic>HTR2A</italic>), genotypes are also associated with the antidepressant efficacy (<xref ref-type="bibr" rid="B19">19</xref>).</p>
<p>Until now, the association between genotype and the efficacy of antidepressants has been detected in a number of studies (<xref ref-type="bibr" rid="B25">25</xref>–<xref ref-type="bibr" rid="B27">27</xref>). For example, it is found that rs6265 in brain-derived neurotrophic factor (<italic>BDNF</italic>) is significantly associated with response to antidepressants in MDD (<xref ref-type="bibr" rid="B28">28</xref>–<xref ref-type="bibr" rid="B31">31</xref>). Some studies show that the SNPs in 5-hydroxytryptamine receptor 1B (<italic>HTR1B</italic>), <italic>HTR1A</italic>, and <italic>HTR2A</italic> are significantly associated with efficacy of antidepressants (<xref ref-type="bibr" rid="B32">32</xref>–<xref ref-type="bibr" rid="B34">34</xref>). Several genome-wide association studies (GWASs) have also been performed to detect the association between SNPs and antidepressant efficacy, such as the Pharmacogenomic Research Network Antidepressant Medication Pharmacogenomic Study (PGRN-AMPS) (<xref ref-type="bibr" rid="B35">35</xref>), the International SSRI Pharmacogenomics Consortium (ISPC) (<xref ref-type="bibr" rid="B36">36</xref>), the Sequenced Treatment Alternatives to Relieve Depression (STAR<sup>*</sup>D) study (<xref ref-type="bibr" rid="B37">37</xref>), the Genome-Based Therapeutic Drugs for Depression (GENDEP) project in whole sample (<xref ref-type="bibr" rid="B38">38</xref>), and the Munich Antidepressant Response Signature (MARS) (<xref ref-type="bibr" rid="B39">39</xref>). Although none of these studies reported the results that achieved the genome-wide significance threshold (<xref ref-type="bibr" rid="B40">40</xref>), a meta-analysis based on the data of PGRN-AMPS, ISPC, and STAR<sup>*</sup>D study identified an SNP (rs2456568) on hypoxanthine phosphoribosyltransferase pseudogene 4 (<italic>HPRTP4</italic>) at the genome-wide significance level (<xref ref-type="bibr" rid="B36">36</xref>). In another GWAS of antidepressant response in Koreans, two significant SNPs (rs7785360 and rs12698828) on autism susceptibility candidate 2 (<italic>AUTS2</italic>) were found to be related to antidepressant response (<xref ref-type="bibr" rid="B41">41</xref>).</p>
<p>Although a number of SNPs have been found to be significantly associated with antidepressant efficacy in treating MDD, it is still unclear how these SNPs affect the interaction between proteins and the drugs, as well as the response of antidepressants. Hence, exploring the correlation between the SNPs and the structures of the corresponding proteins may provide valuable information to understand the molecular mechanism underlying response to antidepressants and help us to develop novel antidepressants. In this article, we implemented a comprehensive curation of SNPs related with antidepressant efficacy from genetic studies and identified the non-synonymous SNPs (nsSNPs) potentially influencing the biological function and structure of the proteins.</p>
</sec>
<sec id="s2" sec-type="materials and methods">
<title>Materials and Methods</title>
<sec>
<title>SNPs Associated With of Antidepressant Efficacy for MDD</title>
<p>First, SNPs associated with antidepressant efficacy were collected. The Pharmacogenomics Knowledgebase (PharmGKB, <ext-link ext-link-type="uri" xlink:href="https://www.pharmgkb.org/">https://www.pharmgkb.org/</ext-link>), a comprehensive resource for clinical information, gene-drug associations, and genotype-phenotype relationships (<xref ref-type="bibr" rid="B42">42</xref>), was queried with different keywords. For terms “antidepressants and depressive disorder, major,” “antidepressants and depressive disorder,” and “antidepressants and depression,” 307, 108, and 193 publications were retrieved respectively. In addition, another list of 245 publications related to other antidepressants was retrieved, among which the contents of 38 publications were closely related to depression. In addition, 225 publications were retrieved from PubMed (<ext-link ext-link-type="uri" xlink:href="https://www.ncbi.nlm.nih.gov/pubmed/">https://www.ncbi.nlm.nih.gov/pubmed/</ext-link>) via the query term “(Depressive Disorder, Major [Mesh]) AND (Antidepressive Agents [Mesh]) AND (Polymorphism, Single Nucleotide [Mesh] OR Pharmacogenetics [Mesh]).” For these publications, the redundant ones were removed. Then, the abstracts of the remaining publications were reviewed, and only studies related to antidepressant response were selected. Most of these studies were GWASs, meta-analysis, and candidate gene analysis of antidepressant responses. In each case, we selected only the SNPs that were significantly associated with the response of antidepressants in MDD. To reduce false-positive findings, the publications reporting negative or insignificant correlations were excluded, although some SNPs explored in these studies might be really associated with antidepressant responses. The full texts of the selected publications were examined to ensure the conclusions were consistent with the content. We narrowed our selection by focusing on those purporting one or more SNPs significantly associated with antidepressant responses. Finally, we retrieved 117 publications (<xref ref-type="fig" rid="F1">Figure 1</xref>).</p>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<p>PRISMA flow diagram illustrating search strategy and studies included in the analysis. PRISMA, Preferred Reporting Items for Systematic Reviews and Meta-Analyses (<ext-link ext-link-type="uri" xlink:href="http://www.prisma-statement.org/">http://www.prisma-statement.org/</ext-link>).</p>
</caption>
<graphic xlink:href="fpsyt-11-00151-g0001"></graphic>
</fig>
</sec>
<sec>
<title>Functional Analysis of nsSNPs</title>
<p>We estimated the influence of amino acid substitution on protein function by several tools, including SIFT (<ext-link ext-link-type="uri" xlink:href="https://sift.bii.a-star.edu.sg/index.html">https://sift.bii.a-star.edu.sg/index.html</ext-link>), PolyPhen-2 (<ext-link ext-link-type="uri" xlink:href="http://genetics.bwh.harvard.edu/pph2/">http://genetics.bwh.harvard.edu/pph2/</ext-link>), and SNAP2 (<ext-link ext-link-type="uri" xlink:href="https://rostlab.org/services/snap2web/">https://rostlab.org/services/snap2web/</ext-link>). SIFT is a tool to predict the change of protein function caused by single amino acid mutation based on homologous protein sequence and the physical properties of amino acids (<xref ref-type="bibr" rid="B43">43</xref>). The output of the tool is a tolerance index score measuring whether an amino acid substitution in a protein is tolerated or damaging, and an SNP with tolerance index score &lt; 0.05 is defined to be deleterious. PolyPhen-2 predicts the effects of human nsSNPs on protein structure and function based on the features of sequence and structural information (<xref ref-type="bibr" rid="B44">44</xref>). The output of PolyPhen-2 is a score ranging from 0 to 1, with larger scores indicating higher likelihood of being damaging. SNAP2 is used to identify the potential effect of mutations by analyzing various sequence and variant features via the artificial neural network. It measures each substitution with a score ranging from −100 (strongly predicted “neutral”) to +100 (strongly predicted “effect”) (<xref ref-type="bibr" rid="B45">45</xref>). SNAP2 is used to differentiate between effect and neutral nsSNPs by thinking about the various sequence and variant features (<xref ref-type="bibr" rid="B45">45</xref>). And the score of each substitution ranges from −100 (strongly predicted “neutral”) to +100 (strongly predicted “effect”).</p>
<p>The mutant protein stability changes were analyzed by I-MUTANT 3.0 (<ext-link ext-link-type="uri" xlink:href="http://gpcr2.biocomp.unibo.it/cgi/predictors/I-Mutant3.0/I-Mutant3.0.cgi">http://gpcr2.biocomp.unibo.it/cgi/predictors/I-Mutant3.0/I-Mutant3.0.cgi</ext-link>). I-MUTANT can detect the changes of protein stability according to single amino acid substitution (<xref ref-type="bibr" rid="B46">46</xref>).</p>
<p>Because an evolutionary conservative an amino acid may be closely related to the protein structure and function, we assessed the conservation of amino acids in a given protein to identify the amino acids whose substitutions may be important for the molecule. The ConSurf (<ext-link ext-link-type="uri" xlink:href="http://consurf.tau.ac.il/2016/">http://consurf.tau.ac.il/2016/</ext-link>) was utilized to evaluate the evolutionary conservation of amino acid positions in protein based on the phylogenetic relationships between homologous protein sequences (<xref ref-type="bibr" rid="B47">47</xref>).</p>
</sec>
<sec>
<title>Analyzing the Structural Fluctuation Due to Deleterious nsSNPs by Molecular Dynamics Simulation</title>
<p>For purpose of detecting the influence of the most deleterious nsSNP on structure, we performed molecular modeling and molecular dynamics (MD) simulation for the native and mutant proteins, respectively. We selected the most closely related protein structure from PDB (Protein Data Bank, <ext-link ext-link-type="uri" xlink:href="https://www.rcsb.org">https://www.rcsb.org</ext-link>). Then, the structure of mutant protein was constructed based on the structure of native protein by SWISS-MODEL (<ext-link ext-link-type="uri" xlink:href="https://swissmodel.expasy.org">https://swissmodel.expasy.org</ext-link>) (<xref ref-type="bibr" rid="B48">48</xref>). Finally, energy minimization and MD simulations were implemented on the native and mutant protein to investigate the structural deviation and fluctuation due to deleterious nsSNPs. All the analyses were implemented by using GROMACS 5.1.4 package (<xref ref-type="bibr" rid="B49">49</xref>).</p>
<p>We used the AMBER99SB-ILDN force field in both native and mutant model systems (<xref ref-type="bibr" rid="B50">50</xref>). The proteins being simulated were at the center of the cubic box. Then, we filled the box with the three-site transferrable intermolecular potential water solvent model and added chlorine ions to the system to neutralize counter-ions. The cutoff for short-range electrostatic and van der Waals interactions was selected as 1.4 nm. In the analysis, we first performed the energy minimizations for the initial structures by using the algorithm of the steepest descent minimization. Next, we conducted the equilibration via a two-stage procedure, that is, an NVT (<italic>N</italic>, constant number; <italic>V</italic>, volume; and <italic>T</italic>, temperature) ensemble was first conducted for 1.0 ns and stabilized the temperature of the system at 300 K; then, an NPT (<italic>N</italic>, constant number; <italic>P</italic>, pressure; and <italic>T</italic>, temperature) ensemble was conducted for 5.0 ns to ensure the system was well-equilibrated with respect to pressure and density. After the system is well-equilibrated at the expected temperature and pressure, we performed the MD simulations for 200 ns to explore the structural deviation and fluctuation of native and mutant protein due to deleterious nsSNPs. Finally, in order to evaluate the convergence of the MD simulations, we calculated the root-mean-square deviation (RMSD). Furthermore, root-mean-square fluctuation (RMSF) was calculated to assess the differences in structural flexibility between the native and mutant proteins. The RMSD and RMSF were obtained from the trajectory files of the MD results, which were produced after the MD simulation.</p>
</sec>
</sec>
<sec id="s3" sec-type="results">
<title>Results</title>
<sec>
<title>SNPs Associated With of Antidepressant Efficacy for MDD</title>
<p>From the available studies, we collected 233 SNPs significantly associated with the antidepressant response (<xref ref-type="supplementary-material" rid="SM1">Supplementary Table 1</xref>). Of these SNPs, 13 were nsSNPs (missense), and 21 were synonymous SNPs in coding region. In the non-coding region, 133 SNPs were intron variant (intronic), and 7 and 2 SNPs were in 3′ UTR and 5′ UTR, respectively (<xref ref-type="fig" rid="F2">Figure 2</xref>). These SNPs were mapped to 110 genes. Among them there were four serotonin receptors, that is, <italic>HTR1A, HTR1B, HTR2A</italic>, and <italic>HTR7</italic>; one dopamine receptor, that is, <italic>DRD3</italic>; two corticotropin-releasing hormone receptors, that is, <italic>CRHR1</italic> and <italic>CRHR2</italic>; two glutamate receptors, that is, <italic>GRIK2</italic> and <italic>GRIK4</italic>; two serotonin biosynthesis genes, that is, <italic>TPH1</italic> and <italic>TPH2</italic>; and some genes encoding transporters, that is, <italic>SLC6A1, SLC6A2, SLC6A3, SLC6A4, SLC39A14</italic>, and <italic>ABCA1</italic>. In addition, some genes were related to drug transport, that is, <italic>CACNA1A, DTNBP1, GDNF, CRH, SLC6A2, SLC6A3, GAL, SNCA</italic>, and <italic>CNR1</italic>; some genes were involved in the exogenous drug catabolic process, that is, <italic>CYP1A2, CYP2C19</italic>, and <italic>CYP2D6</italic>; and some genes were related to response to drug (<italic>COMT, SRP19, NCAM1, NR3C1, CREB1, CRH, CRHBP, CRHR1, BDNF, GSK3B, ITPR2, ARRB2, SERPINE1, RGS17, MAPK1, SNCA</italic>, and <italic>IL1B</italic>). The functional diversity of these genes clearly indicated the complexity of the mechanisms for antidepressant response. In addition, <italic>ABCB1, TPH2, ANO2, ZNF385D</italic>, and <italic>CYP1A2</italic> appeared more frequently in these genes. For these SNPs, most were located in the non-coding regions. Currently, it still remains a significant challenge to explain how SNPs located in intronic or intergenic regions affect drug response. In addition, because synonymous SNPs in the coding region do not change the protein sequence, it is difficult to experimentally address the function of every mutation seen in these regions. Therefore, we focused only on the nsSNPs in the coding region in the following analyses (<xref ref-type="table" rid="T1">Table 1</xref>).</p>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<p>Distribution of SNPs associated with antidepressant response in MDD.</p>
</caption>
<graphic xlink:href="fpsyt-11-00151-g0002"></graphic>
</fig>
<table-wrap id="T1" position="float">
<label>Table 1</label>
<caption>
<p>The nsSNPs associated with antidepressant response in MDD.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>SNP ID</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Gene</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Accession</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Alleles</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>AA change</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">rs2032582</td>
<td align="left" colspan="1" rowspan="1" valign="top">ABCB1</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="NP_000918.2">NP_000918.2</ext-link>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">TCT ⇒ GCT</td>
<td align="left" colspan="1" rowspan="1" valign="top">S 893 A</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">rs6314</td>
<td align="left" colspan="1" rowspan="1" valign="top">HTR2A</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="NP_000612.1">NP_000612.1</ext-link>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">CAT ⇒ TAT</td>
<td align="left" colspan="1" rowspan="1" valign="top">H 452 Y</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">rs6265</td>
<td align="left" colspan="1" rowspan="1" valign="top">BDNF</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="NP_001137277.1">NP_001137277.1</ext-link>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">GTG ⇒ ATG</td>
<td align="left" colspan="1" rowspan="1" valign="top">V 66 M</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">rs1065852</td>
<td align="left" colspan="1" rowspan="1" valign="top">CYP2D6</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="NP_000097.3">NP_000097.3</ext-link>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">CCA ⇒ TCA</td>
<td align="left" colspan="1" rowspan="1" valign="top">P 34 S</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">rs2228479</td>
<td align="left" colspan="1" rowspan="1" valign="top">MC1R</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="NP_002377.4">NP_002377.4</ext-link>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">GTG ⇒ ATG</td>
<td align="left" colspan="1" rowspan="1" valign="top">V 92 M</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">rs11580409</td>
<td align="left" colspan="1" rowspan="1" valign="top">ERICH3</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="NP_001002912.4">NP_001002912.4</ext-link>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">TTA ⇒ GTA</td>
<td align="left" colspan="1" rowspan="1" valign="top">L 1056 V</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">rs6280</td>
<td align="left" colspan="1" rowspan="1" valign="top">DRD3</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="NP_000787.2">NP_000787.2</ext-link>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">GGC ⇒ AGC</td>
<td align="left" colspan="1" rowspan="1" valign="top">G 9 S</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">rs12603700</td>
<td align="left" colspan="1" rowspan="1" valign="top">MIEF2</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="NP_683684.2">NP_683684.2</ext-link>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">GGG ⇒ GAG</td>
<td align="left" colspan="1" rowspan="1" valign="top">G 335 E</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">rs3889402</td>
<td align="left" colspan="1" rowspan="1" valign="top">MIEF2</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="NP_001138372.1">NP_001138372.1</ext-link>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">GCA ⇒ TCA</td>
<td align="left" colspan="1" rowspan="1" valign="top">A 204 S</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">rs3810651</td>
<td align="left" colspan="1" rowspan="1" valign="top">GABRQ</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="NP_061028.3">NP_061028.3</ext-link>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">ATT ⇒ TTT</td>
<td align="left" colspan="1" rowspan="1" valign="top">I 478 F</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">rs4680</td>
<td align="left" colspan="1" rowspan="1" valign="top">COMT</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="NP_000745.1">NP_000745.1</ext-link>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">GTG ⇒ ATG</td>
<td align="left" colspan="1" rowspan="1" valign="top">V 158 M</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">rs117986340</td>
<td align="left" colspan="1" rowspan="1" valign="top">KMT2E</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="NP_061152.3">NP_061152.3</ext-link>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">GGT ⇒ TGT</td>
<td align="left" colspan="1" rowspan="1" valign="top">G 999 C</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">rs2072446</td>
<td align="left" colspan="1" rowspan="1" valign="top">p75NTR</td>
<td align="left" colspan="1" rowspan="1" valign="top">
<ext-link ext-link-type="DDBJ/EMBL/GenBank" xlink:href="NP_002498.1">NP_002498.1</ext-link>
</td>
<td align="left" colspan="1" rowspan="1" valign="top">TCG ⇒ TTG</td>
<td align="left" colspan="1" rowspan="1" valign="top">S 205 L</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec>
<title>Functional Analysis of nsSNPs</title>
<p>To explore the potential influence of amino acid substitutions on the function of protein caused by nsSNPs, we analyzed the 13 nsSNPs via SIFT, PolyPhen, and SNAP2. Of these nsSNPs, each tool predicted 5 as deleterious (<xref ref-type="table" rid="T2">Table 2</xref>), among which 3 nsSNPs (rs1065852, rs3810651, and rs117986340) were commonly identified by SIFT, PolyPhen-2, and SNAP2, which were selected for further investigation. Then, we performed I-MUTANT analysis on the three nsSNPs (<xref ref-type="table" rid="T3">Table 3</xref>). Because the DDG values for all these SNPs were negative (i.e., smaller than 0 kcal/mol), the amino acid substitutions might decrease the stability of the corresponding proteins.</p>
<table-wrap id="T2" position="float">
<label>Table 2</label>
<caption>
<p>The functional analysis of nsSNPs using SIFT, PolyPhen-2, and SNAP2.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th align="center" colspan="2" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">SIFT</th>
<th align="center" colspan="2" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">PolyPhen-2</th>
<th align="center" colspan="3" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">SNAP2</th>
</tr>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">SNP ID</th>
<th align="left" colspan="1" rowspan="1" valign="top">AA change</th>
<th align="center" colspan="1" rowspan="1" valign="top">Score</th>
<th align="left" colspan="1" rowspan="1" valign="top">Predicted effect</th>
<th align="center" colspan="1" rowspan="1" valign="top">Score</th>
<th align="left" colspan="1" rowspan="1" valign="top">Predicted effect</th>
<th align="center" colspan="1" rowspan="1" valign="top">Score</th>
<th align="left" colspan="1" rowspan="1" valign="top">Predicted effect</th>
<th align="center" colspan="1" rowspan="1" valign="top">Expected accuracy%</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">rs2032582</td>
<td align="left" colspan="1" rowspan="1" valign="top">S893A</td>
<td align="center" colspan="1" rowspan="1" valign="top">1.00</td>
<td align="left" colspan="1" rowspan="1" valign="top">Tolerated</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.000</td>
<td align="left" colspan="1" rowspan="1" valign="top">Benign</td>
<td align="center" colspan="1" rowspan="1" valign="top">−50</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neutral</td>
<td align="center" colspan="1" rowspan="1" valign="top">72</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">rs6314</td>
<td align="left" colspan="1" rowspan="1" valign="top">H452Y</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.02</td>
<td align="left" colspan="1" rowspan="1" valign="top">Affect protein function</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.010</td>
<td align="left" colspan="1" rowspan="1" valign="top">Benign</td>
<td align="center" colspan="1" rowspan="1" valign="top">−11</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neutral</td>
<td align="center" colspan="1" rowspan="1" valign="top">57</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">rs6265</td>
<td align="left" colspan="1" rowspan="1" valign="top">V66M</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.18</td>
<td align="left" colspan="1" rowspan="1" valign="top">Tolerated</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.822</td>
<td align="left" colspan="1" rowspan="1" valign="top">Possibly damaging</td>
<td align="center" colspan="1" rowspan="1" valign="top">−41</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neutral</td>
<td align="center" colspan="1" rowspan="1" valign="top">72</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">rs1065852</td>
<td align="left" colspan="1" rowspan="1" valign="top">P34S</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.00</td>
<td align="left" colspan="1" rowspan="1" valign="top">Affect protein function</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.946</td>
<td align="left" colspan="1" rowspan="1" valign="top">Possibly damaging</td>
<td align="center" colspan="1" rowspan="1" valign="top">66</td>
<td align="left" colspan="1" rowspan="1" valign="top">Effect</td>
<td align="center" colspan="1" rowspan="1" valign="top">80</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">rs2228479</td>
<td align="left" colspan="1" rowspan="1" valign="top">V92M</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.28</td>
<td align="left" colspan="1" rowspan="1" valign="top">Tolerated</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.015</td>
<td align="left" colspan="1" rowspan="1" valign="top">Benign</td>
<td align="center" colspan="1" rowspan="1" valign="top">58</td>
<td align="left" colspan="1" rowspan="1" valign="top">Effect</td>
<td align="center" colspan="1" rowspan="1" valign="top">75</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">rs11580409</td>
<td align="left" colspan="1" rowspan="1" valign="top">L1056V</td>
<td align="center" colspan="1" rowspan="1" valign="top">1.00</td>
<td align="left" colspan="1" rowspan="1" valign="top">Tolerated</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="left" colspan="1" rowspan="1" valign="top">Benign</td>
<td align="center" colspan="1" rowspan="1" valign="top">−78</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neutral</td>
<td align="center" colspan="1" rowspan="1" valign="top">87</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">rs6280</td>
<td align="left" colspan="1" rowspan="1" valign="top">G9S</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.24</td>
<td align="left" colspan="1" rowspan="1" valign="top">Tolerated</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="left" colspan="1" rowspan="1" valign="top">Benign</td>
<td align="center" colspan="1" rowspan="1" valign="top">−28</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neutral</td>
<td align="center" colspan="1" rowspan="1" valign="top">61</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">rs12603700</td>
<td align="left" colspan="1" rowspan="1" valign="top">G335E</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.07</td>
<td align="left" colspan="1" rowspan="1" valign="top">Tolerated</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.844</td>
<td align="left" colspan="1" rowspan="1" valign="top">Possibly damaging</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neutral</td>
<td align="center" colspan="1" rowspan="1" valign="top">53</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">rs3889402</td>
<td align="left" colspan="1" rowspan="1" valign="top">A204S</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.00</td>
<td align="left" colspan="1" rowspan="1" valign="top">Affect protein function</td>
<td align="center" colspan="1" rowspan="1" valign="top">0</td>
<td align="left" colspan="1" rowspan="1" valign="top">Benign</td>
<td align="center" colspan="1" rowspan="1" valign="top">−13</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neutral</td>
<td align="center" colspan="1" rowspan="1" valign="top">57</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">rs3810651</td>
<td align="left" colspan="1" rowspan="1" valign="top">I478F</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.00</td>
<td align="left" colspan="1" rowspan="1" valign="top">Affect protein function</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.662</td>
<td align="left" colspan="1" rowspan="1" valign="top">Possibly damaging</td>
<td align="center" colspan="1" rowspan="1" valign="top">67</td>
<td align="left" colspan="1" rowspan="1" valign="top">Effect</td>
<td align="center" colspan="1" rowspan="1" valign="top">80</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">rs4680</td>
<td align="left" colspan="1" rowspan="1" valign="top">V158M</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.09</td>
<td align="left" colspan="1" rowspan="1" valign="top">Tolerated</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.016</td>
<td align="left" colspan="1" rowspan="1" valign="top">Benign</td>
<td align="center" colspan="1" rowspan="1" valign="top">−8</td>
<td align="left" colspan="1" rowspan="1" valign="top">Neutral</td>
<td align="center" colspan="1" rowspan="1" valign="top">53</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">rs117986340</td>
<td align="left" colspan="1" rowspan="1" valign="top">G999C</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.00</td>
<td align="left" colspan="1" rowspan="1" valign="top">Affect protein function</td>
<td align="center" colspan="1" rowspan="1" valign="top">1.000</td>
<td align="left" colspan="1" rowspan="1" valign="top">Probably damaging</td>
<td align="center" colspan="1" rowspan="1" valign="top">5</td>
<td align="left" colspan="1" rowspan="1" valign="top">Effect</td>
<td align="center" colspan="1" rowspan="1" valign="top">53</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">rs2072446</td>
<td align="left" colspan="1" rowspan="1" valign="top">S205L</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.11</td>
<td align="left" colspan="1" rowspan="1" valign="top">Tolerated</td>
<td align="center" colspan="1" rowspan="1" valign="top">0.008</td>
<td align="left" colspan="1" rowspan="1" valign="top">Benign</td>
<td align="center" colspan="1" rowspan="1" valign="top">10</td>
<td align="left" colspan="1" rowspan="1" valign="top">Effect</td>
<td align="center" colspan="1" rowspan="1" valign="top">59</td>
</tr>
</tbody>
</table>
</table-wrap>
<table-wrap id="T3" position="float">
<label>Table 3</label>
<caption>
<p>Protein stability changes after amino acid substitution for nsSNPs predicted by I-MUTANT.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">Gene</th>
<th align="left" colspan="1" rowspan="1" valign="top">SNP ID</th>
<th align="left" colspan="1" rowspan="1" valign="top">AA change</th>
<th align="center" colspan="3" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">I-MUTANT Suite 3.0</th>
</tr>
<tr>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th align="center" colspan="3" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">SVM2 (kcal/mol)</th>
</tr>
<tr>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th align="left" colspan="1" rowspan="1" valign="top">DDG<xref ref-type="table-fn" rid="TN1"><sup>a</sup></xref> value prediction</th>
<th align="left" colspan="1" rowspan="1" valign="top">Prediction effect</th>
<th align="left" colspan="1" rowspan="1" valign="top">RI<xref ref-type="table-fn" rid="TN1"><sup>b</sup></xref></th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">CYP2D6</td>
<td align="left" colspan="1" rowspan="1" valign="top">rs1065852</td>
<td align="left" colspan="1" rowspan="1" valign="top">P34S</td>
<td align="center" colspan="1" rowspan="1" valign="top">−1.21</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decrease</td>
<td align="center" colspan="1" rowspan="1" valign="top">8</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">GABRQ</td>
<td align="left" colspan="1" rowspan="1" valign="top">rs3810651</td>
<td align="left" colspan="1" rowspan="1" valign="top">I478F</td>
<td align="center" colspan="1" rowspan="1" valign="top">−1.68</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decrease</td>
<td align="center" colspan="1" rowspan="1" valign="top">9</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">KMT2E</td>
<td align="left" colspan="1" rowspan="1" valign="top">rs117986340</td>
<td align="left" colspan="1" rowspan="1" valign="top">G999C</td>
<td align="center" colspan="1" rowspan="1" valign="top">−0.89</td>
<td align="left" colspan="1" rowspan="1" valign="top">Decrease</td>
<td align="center" colspan="1" rowspan="1" valign="top">4</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="TN1">
<label>a</label>
<p>Free energy change value.</p>
</fn>
<fn id="TN2">
<label>b</label>
<p><italic>Reliability Index</italic>.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>As we know, the functional important domains of protein usually are highly conserved, which means if an nsSNP is located in conservative domains, it may potentially be important for maintaining the protein structure and function. The conservation of the three deleterious nsSNPs was analyzed using ConSurf. In this study, we performed ConSurf analysis through PSI-BLAST algorithm with default parameters to collect the homologous sequences in UniRef90 protein databases (<xref ref-type="bibr" rid="B47">47</xref>) (<xref ref-type="table" rid="T4">Table 4</xref>). The conservation scores of I478F (rs3810651) and G999C (rs117986340) were 1 and 3, respectively, revealing they were variable. But the conservation score of P34S (rs1065852) was 9, which indicated that the rs1065852 located in a conserved region and may be important for maintaining protein function.</p>
<table-wrap id="T4" position="float">
<label>Table 4</label>
<caption>
<p>The evolutionary conservation analysis of nsSNPs by ConSurf.</p>
</caption>
<table frame="hsides" rules="groups">
<thead>
<tr>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>Gene</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>SNP ID</bold>
</th>
<th align="left" colspan="1" rowspan="1" valign="top">
<bold>AA change</bold>
</th>
<th align="center" colspan="1" rowspan="1" style="border-bottom: thin solid #000000;" valign="top">
<bold>ConSurf</bold>
</th>
</tr>
<tr>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th colspan="1" rowspan="1"></th>
<th align="center" colspan="1" rowspan="1" valign="top">
<bold>UNIREF90</bold>
</th>
</tr>
</thead>
<tbody>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">CYP2D6</td>
<td align="left" colspan="1" rowspan="1" valign="top">rs1065852</td>
<td align="left" colspan="1" rowspan="1" valign="top">P34S</td>
<td align="center" colspan="1" rowspan="1" valign="top">9</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">GABRQ</td>
<td align="left" colspan="1" rowspan="1" valign="top">rs3810651</td>
<td align="left" colspan="1" rowspan="1" valign="top">I478F</td>
<td align="center" colspan="1" rowspan="1" valign="top">1</td>
</tr>
<tr>
<td align="left" colspan="1" rowspan="1" valign="top">KMT2E</td>
<td align="left" colspan="1" rowspan="1" valign="top">rs117986340</td>
<td align="left" colspan="1" rowspan="1" valign="top">G999C</td>
<td align="center" colspan="1" rowspan="1" valign="top">3</td>
</tr>
</tbody>
</table>
</table-wrap>
</sec>
<sec>
<title>Analyzing the Structural Fluctuation Due to Deleterious rs1065852 by Molecular Dynamics Simulation</title>
<p>The mutation of a proline (P) into a serine (S) occurred at position 34 due to deleterious nsSNPs rs1065852 (<xref ref-type="fig" rid="F3">Figure 3</xref>). The difference (amino acid properties, structure) of proline (P) and serine (S) may lead to structural deviation and fluctuation, which may cause the functional deviations between the native and mutant CYP2D6. Thus, we implemented MD simulations for the native and mutant CYP2D6 structures to determine the reason of the structural difference.</p>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<p>Schematic structures of the native (left) and mutant (right) amino acid. The backbone colored red and the same for each amino acid, and side chain unique for each amino acid is colored black; the mutation of proline into serine at position 34 for rs1065852.</p>
</caption>
<graphic xlink:href="fpsyt-11-00151-g0003"></graphic>
</fig>
<p>The native structure of CYP2D6 was obtained from PDB (PDB ID: 3QM4) (<xref ref-type="bibr" rid="B51">51</xref>). Then, we deleted the prinomastat and waters from 3QM4 to construct the initial structure. Then, using 3QM4 as template, the initial structure of mutant was constructed by SWISS-MODEL. After the systems reached being well-equilibrated, 200-ns MD simulations were implemented for the initial structures of native and mutant CYP2D6.</p>
<p>We analyzed the RMSDs for backbone of the native and mutant CYP2D6 to evaluate the convergence of the systems. Root-mean-square deviation indicates the average change in displacement of the selected atoms for a particular frame in respect of a reference coordinate system. The initial structures were used as the references of RMSDs. <xref ref-type="fig" rid="F4">Figure 4</xref> shows that the simulations of native and mutant systems were both converged. In the last 20 ns of simulation, the average RMSD of native structure was 0.228 nm, whereas that of mutant structure was 0.219 nm. In both structures, the structural deviations were observed during simulations. In addition, the fluctuations of RMSDs were smaller at the end of the simulations, which indicated that the simulations generated stable trajectories. Therefore, the results could be used for further analysis.</p>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<p>Root mean square deviations (RMSDs) for the native (black) and mutant (red) of CYP2D6.</p>
</caption>
<graphic xlink:href="fpsyt-11-00151-g0004"></graphic>
</fig>
<p>For purpose of detecting the changes of flexibility between the native and mutant CYP2D6 structures, we calculated the RMSFs. The results are shown in <xref ref-type="fig" rid="F5">Figure 5</xref>. For the RMSFs of native structure, the highest peak was observed near the 230th residue, that is, F-G loop in 3QM4, which indicated that this portion of the native CYP2D6 was flexible. While the RMSFs of mutant in this portion were lower, the flexibility of the F-G loop is reduced compared to the native CYP2D6. In addition, the entrance of the substrate access channel of CYP2D6 is made up of F-G loop, B-C loop, and the loop in the β1 sheet and β2 sheet (<xref ref-type="fig" rid="F6">Figure 6</xref>). The CYP2D6 structural flexibility contributes to its catalytic versatility. As a constituent portion of the substrate access channel, the lower flexibility of F-G loop may affect the substrates that enter into the channel entrance. Hence, this may be the reason for the low enzyme activity of mutant.</p>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption>
<p>Root mean square fluctuations (RMSFs) for the native (gray) and mutant (red) of CYP2D6.</p>
</caption>
<graphic xlink:href="fpsyt-11-00151-g0005"></graphic>
</fig>
<fig id="F6" position="float">
<label>Figure 6</label>
<caption>
<p>The ribbon diagram of CYP2D6; channel entrance is highlighted in purple.</p>
</caption>
<graphic xlink:href="fpsyt-11-00151-g0006"></graphic>
</fig>
</sec>
</sec>
<sec id="s4" sec-type="discussion">
<title>Discussion</title>
<p>Although a number of SNPs are found to be significantly associated with the response of antidepressants in MDD, it is still unclear how they affect the interaction between genes carrying these SNPs and antidepressants. In this study, we collected the SNPs significantly associated with the response of antidepressants and explored the potential mechanism underlying the different antidepressant efficacy among MDD patients. Most of the SNPs were included in the intronic or intergenic regions. For the 13 nsSNPs, three of them (rs1065852, rs3810651, and rs117986340) were predicted to be deleterious to the corresponding proteins. Evolutionary conservation analysis showed that P34S (rs1065852) was the only one located in the conserved protein domain, indicating it may be important for maintaining protein function. Subsequently, the results of the MD simulations revealed that the flexibility of the F-G loop for mutant was reduced compared to the native CYP2D6. As a constituent portion of the substrate access channel, this may affect the substrates that enter into the channel entrance. Hence, this may be the reason for the low enzyme activity of mutant.</p>
<p>In humans, there are ~60 CYP genes (<xref ref-type="bibr" rid="B52">52</xref>). The CYP enzymes are related to the synthesis and metabolism of various molecules and chemicals. As a member of the CYPs superfamily, CYP2D6 plays an important role in drug metabolism. It is responsible for the removal of at least 20% of the compounds, including antidepressants (<xref ref-type="bibr" rid="B53">53</xref>). Earlier studies have found the polymorphisms of CYP2D6 can cause the differences for antidepressant response among MDD patients, among which include CYP2D6 P34S (rs1065852). However, our understanding on the effect of the polymorphisms in CYP2D6 on the antidepressant efficacy is limited (<xref ref-type="bibr" rid="B54">54</xref>), and available studies have found mixed results. Some studies reported negative findings (<xref ref-type="bibr" rid="B55">55</xref>–<xref ref-type="bibr" rid="B57">57</xref>). For instance, Hodgson et al. (<xref ref-type="bibr" rid="B56">56</xref>) analyzed the data from GENDEP and found there was no significant association between CYP2D6 polymorphisms and response to antidepressants. In contrast, some studies reported positive associations between CYP2D6 polymorphisms and response to antidepressants (<xref ref-type="bibr" rid="B58">58</xref>–<xref ref-type="bibr" rid="B61">61</xref>). For example, Zastrozhin et al. (<xref ref-type="bibr" rid="B59">59</xref>) found that patients with 1846G&gt;A of CYP2D6 polymorphism (rs3892097) had significantly reduced efficacy of fluvoxamine. For the P34S (rs1065852) substitution in CYP2D6. Tsai et al. (<xref ref-type="bibr" rid="B60">60</xref>) suggested that CYP2D6 polymorphisms (CYP2D6<sup>*</sup>4,CYP2D6<sup>*</sup>5, and CYP2D6<sup>*</sup>10) may be predicting patient treatment outcomes. In our study, we obtained the results of Han et al. (<xref ref-type="bibr" rid="B61">61</xref>), which found the P amino acid of the P34S (rs1065852) substitution in CYP2D6 is a favorable factor in the treatment of escitalopram for MDD and that the P34S (rs1065852) substitution may be a good genetic marker for predicting the treatment outcomes of escitalopram.</p>
<p>The results of the MD simulations indicated that the flexibility of the F-G loop for mutant was reduced compared to the native CYP2D6. The P34S(rs1065852) substitution is located in a highly conserved region encoding the proline-rich N-terminus in the three-dimensional structure of CYP2D6 (<xref ref-type="bibr" rid="B51">51</xref>), which was consistent with the results of our previous evolutionary conservation analysis. In addition, we analyzed the difference between the native and mutant amino acids in terms of amino acid properties, structure, and domains by HOPE (<ext-link ext-link-type="uri" xlink:href="http://www.cmbi.ru.nl/hope/">http://www.cmbi.ru.nl/hope/</ext-link>), which is a tool that analyzes the structural effects of a point mutation in protein sequence (<xref ref-type="bibr" rid="B62">62</xref>). For amino acid properties, the serine is smaller than the native residue proline at position 34, which may cause a loss of external interactions (<xref ref-type="bibr" rid="B62">62</xref>). And the native residue is more hydrophobic than the mutant residue (<xref ref-type="bibr" rid="B62">62</xref>), which might cause the damage of hydrophobic interactions with other molecules on the surface of CYP2D6. From the comparison of the structures of mutant and original amino acids, prolines are very rigid and produce a particular backbone conformation, which might be needed at this position. The amino acid substitution can disturb this particular conformation. For domain, the mutant residue may affect the domain that is important for the activity of CYP2D6 (<xref ref-type="bibr" rid="B62">62</xref>). Therefore, structural perturbation of this region may cause the change of protein stability and enzyme activity. Research showed that the P34S (rs1065852) affected the hydrogen bonding network in the interdomain between of the N-terminal and the F-G loop (<xref ref-type="bibr" rid="B63">63</xref>, <xref ref-type="bibr" rid="B64">64</xref>). The results indicated that the hydrogen bonds located in the interdomain between the N-terminal and the F-G loop in mutant were fewer than in native CYP2D6. And the hydrophobic effect may alter the structure of F-G loop. Hence, the change of N-terminal loop due to the mutant P34S (rs1065852) influenced the hydrogen bonding network and ultimately may alter the structure of F-G loop. The mutation might disturb signal transfer from N-terminal to the distant protein from the mutated position through hydrophobic effect (<xref ref-type="bibr" rid="B64">64</xref>) and influence the structure of the distant residues from the mutant position. Other studies also reported the activity of mutant CYP2D6 has significantly reduced <italic>in vivo</italic> (<xref ref-type="bibr" rid="B65">65</xref>–<xref ref-type="bibr" rid="B67">67</xref>). The results of an early study suggested that the mutant of P34S affected the enzymatic activities (<xref ref-type="bibr" rid="B68">68</xref>). Kim et al. (<xref ref-type="bibr" rid="B69">69</xref>) indicated that the loss of functions in CYP2D6 alleles can be attributed to the P34S(rs1065852) substitution. These reports are consistent with our findings. The findings may facilitate us to understand why the P amino acid of the P34S (rs1065852) substitution in CYP2D6 is a favorable factor than S amino acid in the treatment of escitalopram for MDD and provide theoretical basis for the development of new antidepressants and personalized medicine in MDD.</p>
<p>Although rs3810651 and rs117986340 are not located in highly conserved regions, their involvements in the antidepressant efficacy are clear. SNP rs3810651 (I478F) is located in the coding region of γ-aminobutyric acid type A receptor, subunit theta (<italic>GABRQ</italic>), whose genotype AA + AT (F) is significantly associated with increased response to venlafaxine in people with MDD as compared to genotype TT(I) (<xref ref-type="bibr" rid="B70">70</xref>). GABRQ is the site of action of a number of important pharmacologic agents (<xref ref-type="bibr" rid="B71">71</xref>). The mutated residue phenylalanine is bigger than the original residue isoleucine at position 478 for rs3810651, and the phenylalanine is located in a domain that is important for the activity of GABRQ. Therefore, the mutation might have influence on the activity of the extracellular ligand-gated ion channel (<xref ref-type="bibr" rid="B62">62</xref>). The SNP rs117986340 (G999C)is located on lysine methyltransferase 2E (<italic>KMT2E</italic>), whose genotype GG(G) is significantly associated with increased response to duloxetine in people with MDD as compared to genotype GT(C) (<xref ref-type="bibr" rid="B72">72</xref>). The original residue glycine at position 999 is smaller and more hydrophilic than the mutated residue cysteine, which might be necessary for the function of KMT2E. In view of structure, glycine is more flexible to generate the torsion angles compared with the mutant residue; the mutation will result in an inaccurate conformation and disturb the local structure (<xref ref-type="bibr" rid="B62">62</xref>).</p>
<p>Besides, of the 13 nsSNPs, several other SNPs are also frequently studied. It is found that rs6314 genotype AG is associated with improved response when treated with paroxetine in people with MDD as compared to genotypes AA + GG (<xref ref-type="bibr" rid="B73">73</xref>, <xref ref-type="bibr" rid="B74">74</xref>). The <italic>HTR2A</italic> carrying rs6314 is related to postsynaptic serotonin signaling and is a target for many antidepressants (<xref ref-type="bibr" rid="B75">75</xref>). HTR2A involves the serotonin synthesis, release, reuptake, and mediation of SSRIs in human brain. Therefore, the polymorphisms of HTR2A are associated with the response of antidepressants in MDD (<xref ref-type="bibr" rid="B34">34</xref>, <xref ref-type="bibr" rid="B76">76</xref>, <xref ref-type="bibr" rid="B77">77</xref>). The variation may be associated with antidepressant response by affecting serotonin signaling cascades (<xref ref-type="bibr" rid="B73">73</xref>). The rs6314 is an SNP in the third exon of <italic>HTR2A</italic> gene and leads to the change between histidine (His) and tyrosine (Tyr) at position 452. In addition, rs6311, rs17288723, rs7997012, rs9316233, rs6313, and rs2770296 of this gene are also significantly associated with antidepressant efficacy in MDD. This may result in the changes in protein structure and affect the interaction between HTR2A and antidepressants. In addition, several earlier studies found that rs6265 genotypes in <italic>BDNF</italic> were significantly associated with the response to antidepressants in MDD (<xref ref-type="bibr" rid="B29">29</xref>–<xref ref-type="bibr" rid="B31">31</xref>). <italic>BDNF</italic> is related to the survival of existing neurons, as well as the development and differentiation of new neurons and synapses in the central nervous system (<xref ref-type="bibr" rid="B78">78</xref>). The rs6265(Val66Met) locates within the signal peptide; it may be important for the maturation of the protein (<xref ref-type="bibr" rid="B62">62</xref>). Mutation may cause the change in structure and function of BDNF and ultimately result in the difference of antidepressant efficacy in individuals.</p>
<p>Undeniably, there are some limitations in the current study. First, our results depend on the retrieved existing studies that purported the SNPs associated with the antidepressant efficacy. Given that identification of such genetic factors is an ongoing process, more SNPs and genes may be identified in the future. Second, because of the difference in methods and sample size of the available studies, it is possible that some SNPs with nominal or moderate association with the antidepressant efficacy are not included in our analysis, and some SNPs collected might be false positive; hence, in order to obtain a more comprehensive SNPs list and validate the results, further investigation with a larger sample size or different technical approaches is needed. Finally, although we combined different approaches to identify the deleterious nsSNPs that may influence the structure and function of proteins, some may still be missed. With the SNP data and analysis approaches becoming more comprehensive and accurate, these problems would be avoided.</p>
</sec>
<sec id="s5" sec-type="conclusions">
<title>Conclusion</title>
<p>In this study, we conducted a computational analysis on the SNPs associated with antidepressant efficacy. From 233 SNPs collected from available human pharmacogenetic studies, we screened 13 nsSNPs and found three of them (i.e., rs1065852, rs3810651, and rs117986340) were likely to be deleterious in the encoding proteins, particularly P34S (rs1065852) in CYP2D6. Results of the subsequent MD simulation regarding rs1065852 indicated that the flexibility of the F-G loop for mutant was reduced compared to the native CYP2D6, which may be responsible for the decrease in enzyme activity by hindering the substrate recognition and access. In addition, our results may provide theoretical basis for the development of new antidepressants and personalized medicine in MDD.</p>
</sec>
<sec id="s6" sec-type="data-availability">
<title>Data Availability Statement</title>
<p>All datasets generated for this study are included in the article/<xref ref-type="sec" rid="s8">Supplementary Material</xref>.</p>
</sec>
<sec id="s7">
<title>Author Contributions</title>
<p>JX, MY, YP, and JW: conceived, designed, and performed the experiments and wrote the paper. JX, MY, and YP: analyzed the data.</p>
<sec>
<title>Conflict of Interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<p><bold>Funding.</bold> This study was supported in part by grants from National Key Research and Development Program of China (No. 2016YFC0906300), National Natural Science Foundation of China (Nos. 31271411 and 91746205). The funding bodies played no role in the design of the study and collection, analysis and interpretation of data, or in writing of the manuscript.</p>
</fn>
</fn-group>
<sec id="s8" sec-type="supplementary-material">
<title>Supplementary Material</title>
<p>The Supplementary Material for this article can be found online at: <ext-link ext-link-type="uri" xlink:href="https://www.frontiersin.org/articles/10.3389/fpsyt.2020.00151/full#supplementary-material">https://www.frontiersin.org/articles/10.3389/fpsyt.2020.00151/full#supplementary-material</ext-link></p>
<supplementary-material content-type="local-data" id="SM1">
<media xlink:href="Table_1.DOC">
<caption>
<p>Click here for additional data file.</p>
</caption>
</media>
</supplementary-material>
</sec>
<ref-list>
<title>References</title>
<ref id="B1">
<label>1.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kessler</surname><given-names>RC</given-names></name><name><surname>Bromet</surname><given-names>EJ</given-names></name></person-group>. <article-title>The epidemiology of depression across cultures</article-title>. <source/>Annu Rev Public Health. (<year>2013</year>) <volume>34</volume>:<fpage>119</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1146/annurev-publhealth-031912-114409</pub-id><pub-id pub-id-type="pmid">23514317</pub-id></mixed-citation>
</ref>
<ref id="B2">
<label>2.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malhi</surname><given-names>GS</given-names></name><name><surname>Mann</surname><given-names>JJ</given-names></name></person-group>. <article-title>Depression</article-title>. <source/>Lancet. (<year>2018</year>) <volume>392</volume>:<fpage>2299</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1016/S0140-6736(18)31948-2</pub-id><pub-id pub-id-type="pmid">30396512</pub-id></mixed-citation>
</ref>
<ref id="B3">
<label>3.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunn</surname><given-names>EC</given-names></name><name><surname>Brown</surname><given-names>RC</given-names></name><name><surname>Dai</surname><given-names>Y</given-names></name><name><surname>Rosand</surname><given-names>J</given-names></name><name><surname>Nugent</surname><given-names>NR</given-names></name><name><surname>Amstadter</surname><given-names>AB</given-names></name><etal></etal></person-group>. <article-title>Genetic determinants of depression: recent findings and future directions</article-title>. <source/>Harv Rev Psychiatr. (<year>2015</year>) <volume>23</volume>:<fpage>1</fpage>–<lpage>18</lpage>. <pub-id pub-id-type="doi">10.1097/HRP.0000000000000054</pub-id><pub-id pub-id-type="pmid">25563565</pub-id></mixed-citation>
</ref>
<ref id="B4">
<label>4.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>AB</given-names></name><name><surname>Bousman</surname><given-names>CA</given-names></name><name><surname>Ng</surname><given-names>C</given-names></name><name><surname>Berk</surname><given-names>M</given-names></name></person-group>. <article-title>Antidepressant pharmacogenetics</article-title>. <source/>Curr Opin Psychiatr. (<year>2014</year>) <volume>27</volume>:<fpage>43</fpage>–<lpage>51</lpage>. <pub-id pub-id-type="doi">10.1097/YCO.0000000000000023</pub-id><pub-id pub-id-type="pmid">24270480</pub-id></mixed-citation>
</ref>
<ref id="B5">
<label>5.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muglia</surname><given-names>P</given-names></name><name><surname>Tozzi</surname><given-names>F</given-names></name><name><surname>Galwey</surname><given-names>NW</given-names></name><name><surname>Francks</surname><given-names>C</given-names></name><name><surname>Upmanyu</surname><given-names>R</given-names></name><name><surname>Kong</surname><given-names>XQ</given-names></name><etal></etal></person-group>. <article-title>Genome-wide association study of recurrent major depressive disorder in two European case-control cohorts</article-title>. <source/>Mol Psychiatry. (<year>2010</year>) <volume>15</volume>:<fpage>589</fpage>–<lpage>601</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2008.131</pub-id><pub-id pub-id-type="pmid">19107115</pub-id></mixed-citation>
</ref>
<ref id="B6">
<label>6.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sheehan</surname><given-names>DV</given-names></name><name><surname>Nakagome</surname><given-names>K</given-names></name><name><surname>Asami</surname><given-names>Y</given-names></name><name><surname>Pappadopulos</surname><given-names>EA</given-names></name><name><surname>Boucher</surname><given-names>M</given-names></name></person-group>. <article-title>Restoring function in major depressive disorder: a systematic review</article-title>. <source/>J Affect Disord. (<year>2017</year>) <volume>215</volume>:<fpage>299</fpage>–<lpage>313</lpage>. <pub-id pub-id-type="doi">10.1016/j.jad.2017.02.029</pub-id><pub-id pub-id-type="pmid">28364701</pub-id></mixed-citation>
</ref>
<ref id="B7">
<label>7.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wakefield</surname><given-names>JC</given-names></name><name><surname>Schmitz</surname><given-names>MF</given-names></name><name><surname>First</surname><given-names>MB</given-names></name><name><surname>Horwitz</surname><given-names>AV</given-names></name></person-group>. <article-title>Extending the bereavement exclusion for major depression to other losses: evidence from the National Comorbidity Survey</article-title>. <source/>Arch Gen Psychiatr. (<year>2007</year>) <volume>64</volume>:<fpage>433</fpage>–<lpage>440</lpage>. <pub-id pub-id-type="doi">10.1001/archpsyc.64.4.433</pub-id><pub-id pub-id-type="pmid">17404120</pub-id></mixed-citation>
</ref>
<ref id="B8">
<label>8.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ustün</surname><given-names>TB</given-names></name><name><surname>Ayuso-Mateos</surname><given-names>JL</given-names></name><name><surname>Chatterji</surname><given-names>S</given-names></name><name><surname>Mathers</surname><given-names>C</given-names></name><name><surname>Murray</surname><given-names>CJ</given-names></name></person-group>. <article-title>Global burden of depressive disorders in the year</article-title> (<year>2000</year>). <source/>Br J Psychiatr. (<year>2004</year>) <volume>184</volume>:<fpage>386</fpage>–<lpage>92</lpage>. <pub-id pub-id-type="doi">10.1192/bjp.184.5.386</pub-id><pub-id pub-id-type="pmid">15123501</pub-id></mixed-citation>
</ref>
<ref id="B9">
<label>9.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bruffaerts</surname><given-names>R</given-names></name><name><surname>Vilagut</surname><given-names>G</given-names></name><name><surname>Demyttenaere</surname><given-names>K</given-names></name><name><surname>Alonso</surname><given-names>J</given-names></name><name><surname>Alhamzawi</surname><given-names>A</given-names></name><name><surname>Andrade</surname><given-names>LH</given-names></name><etal></etal></person-group>. <article-title>Role of common mental and physical disorders in partial disability around the world</article-title>. <source/>Br J Psychiatr. (<year>2012</year>) <volume>200</volume>:<fpage>454</fpage>–<lpage>61</lpage>. <pub-id pub-id-type="doi">10.1192/bjp.bp.111.097519</pub-id><pub-id pub-id-type="pmid">22539779</pub-id></mixed-citation>
</ref>
<ref id="B10">
<label>10.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Greenberg</surname><given-names>PE</given-names></name><name><surname>Fournier</surname><given-names>AA</given-names></name><name><surname>Sisitsky</surname><given-names>T</given-names></name><name><surname>Pike</surname><given-names>CT</given-names></name><name><surname>Kessler</surname><given-names>RC</given-names></name></person-group>. <article-title>The economic burden of adults with major depressive disorder in the United States (2005 and 2010)</article-title>. <source/>J Clin Psychiatr. (<year>2015</year>) <volume>76</volume>:<fpage>155</fpage>–<lpage>62</lpage>. <pub-id pub-id-type="doi">10.4088/JCP.14m09298</pub-id><pub-id pub-id-type="pmid">25742202</pub-id></mixed-citation>
</ref>
<ref id="B11">
<label>11.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>CR</given-names></name><name><surname>Qin</surname><given-names>X</given-names></name></person-group>. <article-title>Depression hurts, depression costs: the medical spending attributable to depression and depressive symptoms in China</article-title>. <source/>Health Econ. (<year>2018</year>) <volume>27</volume>:<fpage>525</fpage>–<lpage>44</lpage>. <pub-id pub-id-type="doi">10.1002/hec.3604</pub-id><pub-id pub-id-type="pmid">28990318</pub-id></mixed-citation>
</ref>
<ref id="B12">
<label>12.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lepine</surname><given-names>JP</given-names></name><name><surname>Briley</surname><given-names>M</given-names></name></person-group>. <article-title>The increasing burden of depression</article-title>. <source/>Neuropsychiatr Dis Treat. (<year>2011</year>) <volume>7</volume>:<fpage>3</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.2147/NDT.S19617</pub-id><pub-id pub-id-type="pmid">21750622</pub-id></mixed-citation>
</ref>
<ref id="B13">
<label>13.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>E</given-names></name><name><surname>Lane</surname><given-names>HY</given-names></name></person-group>. <article-title>Genome-wide association studies in pharmacogenomics of antidepressants</article-title>. <source/>Pharmacogenomics. (<year>2015</year>) <volume>16</volume>:<fpage>555</fpage>–<lpage>66</lpage>. <pub-id pub-id-type="doi">10.2217/pgs.15.5</pub-id><pub-id pub-id-type="pmid">25916525</pub-id></mixed-citation>
</ref>
<ref id="B14">
<label>14.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Singh</surname><given-names>AB</given-names></name><name><surname>Bousman</surname><given-names>CA</given-names></name></person-group>. <article-title>Antidepressant pharmacogenetics</article-title>. <source/>Am J Psychiatr. (<year>2017</year>) <volume>174</volume>:<fpage>417</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ajp.2017.17020173</pub-id><pub-id pub-id-type="pmid">28457163</pub-id></mixed-citation>
</ref>
<ref id="B15">
<label>15.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zajecka</surname><given-names>JM</given-names></name></person-group>. <article-title>Treating depression to remission</article-title>. <source/>J Clin Psychiatr. (<year>2003</year>) <volume>64</volume>:<fpage>7</fpage>–<lpage>12</lpage>. Available online at: <ext-link ext-link-type="uri" xlink:href="https://www.psychiatrist.com/JCP/article/Pages/2003/v64s15/v64s1503.aspx">https://www.psychiatrist.com/JCP/article/Pages/2003/v64s15/v64s1503.aspx</ext-link><pub-id pub-id-type="pmid">14658985</pub-id></mixed-citation>
</ref>
<ref id="B16">
<label>16.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nierenberg</surname><given-names>AA</given-names></name></person-group>. <article-title>Predictors of response to antidepressants general principles and clinical implications</article-title>. <source/>Psychiatr Clin North Am. (<year>2003</year>) <volume>26</volume>:<fpage>345</fpage>–<lpage>52</lpage>. <pub-id pub-id-type="doi">10.1016/S0193-953X(02)00105-3</pub-id><pub-id pub-id-type="pmid">12778837</pub-id></mixed-citation>
</ref>
<ref id="B17">
<label>17.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perlis</surname><given-names>RH</given-names></name></person-group>. <article-title>Pharmacogenetic studies of antidepressant response: how far from the clinic?</article-title>
<source/>Psychiatr Clin North Am. (<year>2007</year>) <volume>30</volume>:<fpage>125</fpage>–<lpage>38</lpage>. <pub-id pub-id-type="doi">10.1016/j.psc.2006.12.004</pub-id><pub-id pub-id-type="pmid">17362808</pub-id></mixed-citation>
</ref>
<ref id="B18">
<label>18.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'Reilly</surname><given-names>RL</given-names></name><name><surname>Bogue</surname><given-names>L</given-names></name><name><surname>Singh</surname><given-names>SM</given-names></name></person-group>. <article-title>Pharmacogenetic response to antidepressants in a multicase family with affective disorder</article-title>. <source/>Biol Psychiatr. (<year>1994</year>) <volume>36</volume>:<fpage>467</fpage>–<lpage>71</lpage>. <pub-id pub-id-type="doi">10.1016/0006-3223(94)90642-4</pub-id><pub-id pub-id-type="pmid">7811843</pub-id></mixed-citation>
</ref>
<ref id="B19">
<label>19.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porcelli</surname><given-names>S</given-names></name><name><surname>Drago</surname><given-names>A</given-names></name><name><surname>Fabbri</surname><given-names>C</given-names></name><name><surname>Gibiino</surname><given-names>S</given-names></name><name><surname>Calati</surname><given-names>R</given-names></name><name><surname>Serretti</surname><given-names>A</given-names></name></person-group>. <article-title>Pharmacogenetics of antidepressant response</article-title>. <source/>J Psychiatry Neurosci. (<year>2011</year>) <volume>36</volume>:<fpage>87</fpage>–<lpage>113</lpage>. <pub-id pub-id-type="doi">10.1503/jpn.100059</pub-id><pub-id pub-id-type="pmid">21172166</pub-id></mixed-citation>
</ref>
<ref id="B20">
<label>20.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Binder</surname><given-names>EB</given-names></name><name><surname>Holsboer</surname><given-names>F</given-names></name></person-group>. <article-title>Pharmacogenomics and antidepressant drugs</article-title>. <source/>Ann Med. (<year>2006</year>) <volume>38</volume>:<fpage>82</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1080/07853890600551045</pub-id><pub-id pub-id-type="pmid">16581694</pub-id></mixed-citation>
</ref>
<ref id="B21">
<label>21.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zackrisson</surname><given-names>AL</given-names></name><name><surname>Lindblom</surname><given-names>B</given-names></name><name><surname>Ahlner</surname><given-names>J</given-names></name></person-group>. <article-title>High frequency of occurrence of CYP2D6 gene duplication/multiduplication indicating ultrarapid metabolism among suicide cases</article-title>. <source/>Clin Pharmacol Ther. (<year>2010</year>) <volume>88</volume>:<fpage>354</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/clpt.2009.216</pub-id><pub-id pub-id-type="pmid">19907421</pub-id></mixed-citation>
</ref>
<ref id="B22">
<label>22.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Höfer</surname><given-names>P</given-names></name><name><surname>Schosser</surname><given-names>A</given-names></name><name><surname>Calati</surname><given-names>R</given-names></name><name><surname>Serretti</surname><given-names>A</given-names></name><name><surname>Massat</surname><given-names>I</given-names></name><name><surname>Kocabas</surname><given-names>NA</given-names></name><etal></etal></person-group>
<article-title>Cytochrome P450 CYP1A2, CYP2C9, CYP2C19 and CYP2D6 genes are not associated with response and remission in a sample of depressive patients</article-title>. <source/>Int Clin Psychopharmacol. (<year>2009</year>) <volume>24</volume>:<fpage>250</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1097/YIC.0b013e32832e5b0d</pub-id><pub-id pub-id-type="pmid">19593158</pub-id></mixed-citation>
</ref>
<ref id="B23">
<label>23.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peters</surname><given-names>EJ</given-names></name><name><surname>Slager</surname><given-names>SL</given-names></name><name><surname>Kraft</surname><given-names>JB</given-names></name><name><surname>Jenkins</surname><given-names>GD</given-names></name><name><surname>Reinalda</surname><given-names>MS</given-names></name><name><surname>McGrath</surname><given-names>PJ</given-names></name><etal></etal></person-group>. <article-title>Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR<sup>*</sup>D sample</article-title>. <source/>PLoS ONE. (<year>2008</year>) <volume>3</volume>:<fpage>e1872</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0001872</pub-id><pub-id pub-id-type="pmid">18382661</pub-id></mixed-citation>
</ref>
<ref id="B24">
<label>24.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laika</surname><given-names>B</given-names></name><name><surname>Leucht</surname><given-names>S</given-names></name><name><surname>Heres</surname><given-names>S</given-names></name><name><surname>Steimer</surname><given-names>W</given-names></name></person-group>. <article-title>Intermediate metabolizer: increased side effects in psychoactive drug therapy. The key to cost-effectiveness of pretreatment CYP2D6 screening?</article-title>
<source/>Pharmacogenomics J. (<year>2009</year>). <volume>9</volume>:<fpage>395</fpage>–<lpage>403</lpage>. <pub-id pub-id-type="doi">10.1038/tpj.2009.23</pub-id><pub-id pub-id-type="pmid">19451914</pub-id></mixed-citation>
</ref>
<ref id="B25">
<label>25.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>M</given-names></name><name><surname>Neavin</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>D</given-names></name><name><surname>Biernacka</surname><given-names>J</given-names></name><name><surname>Hall-Flavin</surname><given-names>D</given-names></name><name><surname>Bobo</surname><given-names>WV</given-names></name><etal></etal></person-group>. <article-title>TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics</article-title>. <source/>Mol Psychiatr. (<year>2016</year>) <volume>21</volume>:<fpage>1717</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1038/mp.2016.6</pub-id><pub-id pub-id-type="pmid">26903268</pub-id></mixed-citation>
</ref>
<ref id="B26">
<label>26.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nouraei</surname><given-names>H</given-names></name><name><surname>Firouzabadi</surname><given-names>N</given-names></name><name><surname>Mandegary</surname><given-names>A</given-names></name><name><surname>Zomorrodian</surname><given-names>K</given-names></name><name><surname>Bahramali</surname><given-names>E</given-names></name><name><surname>Shayesteh</surname><given-names>MRH</given-names></name><etal></etal></person-group>. <article-title>Glucocorticoid receptor genetic variants and response to fluoxetine in major depressive disorder</article-title>. <source/>J Neuropsychiatry Clin Neurosci. (<year>2018</year>) <volume>30</volume>:<fpage>45</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1176/appi.neuropsych.16120322</pub-id><pub-id pub-id-type="pmid">28641498</pub-id></mixed-citation>
</ref>
<ref id="B27">
<label>27.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Petit</surname><given-names>AC</given-names></name><name><surname>El Asmar</surname><given-names>K</given-names></name><name><surname>David</surname><given-names>DJ</given-names></name><name><surname>Gardier</surname><given-names>AM</given-names></name><name><surname>Becquemont</surname><given-names>L</given-names></name><name><surname>Fève</surname><given-names>B</given-names></name><etal></etal></person-group>. <article-title>The association of beta-arrestin2 polymorphisms with response to antidepressant treatment in depressed patients</article-title>. <source/>Prog Neuropsychopharmacol Biol Psychiatr. (<year>2018</year>) <volume>81</volume>:<fpage>74</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2017.10.006</pub-id><pub-id pub-id-type="pmid">29031912</pub-id></mixed-citation>
</ref>
<ref id="B28">
<label>28.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Murphy</surname><given-names>GM</given-names><suffix>Jr</suffix></name><name><surname>Sarginson</surname><given-names>JE</given-names></name><name><surname>Ryan</surname><given-names>HS</given-names></name><name><surname>O'Hara</surname><given-names>R</given-names></name><name><surname>Schatzberg</surname><given-names>AF</given-names></name><name><surname>Lazzeroni</surname><given-names>LC</given-names></name></person-group>. <article-title>BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression</article-title>. <source/>Pharmacogenet Genomics. (<year>2013</year>) <volume>23</volume>:<fpage>301</fpage>–<lpage>13</lpage>. <pub-id pub-id-type="doi">10.1097/FPC.0b013e328360b175</pub-id><pub-id pub-id-type="pmid">23619509</pub-id></mixed-citation>
</ref>
<ref id="B29">
<label>29.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>XC</given-names></name><name><surname>Xu</surname><given-names>DJ</given-names></name><name><surname>Chen</surname><given-names>GH</given-names></name><name><surname>Xia</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>LN</given-names></name></person-group>. <article-title>Association of 2 neurotrophic factor polymorphisms with efficacy of paroxetine in patients with major depressive disorder in a Chinese population</article-title>. <source/>Ther Drug Monit. (<year>2014</year>) <volume>36</volume>:<fpage>612</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1097/FTD.0000000000000062</pub-id><pub-id pub-id-type="pmid">24577123</pub-id></mixed-citation>
</ref>
<ref id="B30">
<label>30.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colle</surname><given-names>R</given-names></name><name><surname>Gressier</surname><given-names>F</given-names></name><name><surname>Verstuyft</surname><given-names>C</given-names></name><name><surname>Deflesselle</surname><given-names>E</given-names></name><name><surname>Lépine</surname><given-names>JP</given-names></name><name><surname>Ferreri</surname><given-names>F</given-names></name><etal></etal></person-group>. <article-title>Brain-derived neurotrophic factor Val66Met polymorphism and 6-month antidepressant remission in depressed Caucasian patients</article-title>. <source/>J Affect Disord. (<year>2015</year>) <volume>175</volume>:<fpage>233</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1016/j.jad.2015.01.013</pub-id><pub-id pub-id-type="pmid">25658497</pub-id></mixed-citation>
</ref>
<ref id="B31">
<label>31.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chi</surname><given-names>MH</given-names></name><name><surname>Chang</surname><given-names>HH</given-names></name><name><surname>Lee</surname><given-names>SY</given-names></name><name><surname>Lee</surname><given-names>IH</given-names></name><name><surname>Gean</surname><given-names>PW</given-names></name><name><surname>Yang</surname><given-names>YK</given-names></name><etal></etal></person-group>. <article-title>Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder</article-title>. <source/>J Affect Disord. (<year>2010</year>) <volume>126</volume>:<fpage>430</fpage>–<lpage>5</lpage>. <pub-id pub-id-type="doi">10.1016/j.jad.2010.07.006</pub-id><pub-id pub-id-type="pmid">20674983</pub-id></mixed-citation>
</ref>
<ref id="B32">
<label>32.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gassó</surname><given-names>P</given-names></name><name><surname>Rodríguez</surname><given-names>N</given-names></name><name><surname>Blázquez</surname><given-names>A</given-names></name><name><surname>Monteagudo</surname><given-names>A</given-names></name><name><surname>Boloc</surname><given-names>D</given-names></name><name><surname>Plana</surname><given-names>MT</given-names></name><etal></etal></person-group>. <article-title>Epigenetic and genetic variants in the HTR1B gene and clinical improvement in children and adolescents treated with fluoxetine</article-title>. <source/>Prog Neuropsychopharmacol Biol Psychiatr. (<year>2017</year>) <volume>75</volume>:<fpage>28</fpage>–<lpage>34</lpage>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2016.12.003</pub-id><pub-id pub-id-type="pmid">28025020</pub-id></mixed-citation>
</ref>
<ref id="B33">
<label>33.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kato</surname><given-names>M</given-names></name><name><surname>Fukuda</surname><given-names>T</given-names></name><name><surname>Wakeno</surname><given-names>M</given-names></name><name><surname>Okugawa</surname><given-names>G</given-names></name><name><surname>Takekita</surname><given-names>Y</given-names></name><name><surname>Watanabe</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>Effect of 5-HT1A gene polymorphisms on antidepressant response in major depressive disorder</article-title>. <source/>Am J Med Genet B Neuropsychiatr Genet. (<year>2009</year>) <volume>150</volume>:<fpage>115</fpage>–<lpage>23</lpage>. <pub-id pub-id-type="doi">10.1002/ajmg.b.30783</pub-id></mixed-citation>
</ref>
<ref id="B34">
<label>34.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>JY</given-names></name><name><surname>Jiang</surname><given-names>MY</given-names></name><name><surname>Kan</surname><given-names>ZM</given-names></name><name><surname>Chu</surname><given-names>Y</given-names></name></person-group>. <article-title>Influence of 5-HTR2A genetic polymorphisms on the efficacy of antidepressants in the treatment of major depressive disorder: a meta-analysis</article-title>. <source/>J Affect Disord. (<year>2014</year>) <volume>168</volume>:<fpage>430</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.jad.2014.06.012</pub-id><pub-id pub-id-type="pmid">25108775</pub-id></mixed-citation>
</ref>
<ref id="B35">
<label>35.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mrazek</surname><given-names>DA</given-names></name><name><surname>Biernacka</surname><given-names>JM</given-names></name><name><surname>McAlpine</surname><given-names>DE</given-names></name><name><surname>Benitez</surname><given-names>J</given-names></name><name><surname>Karpyak</surname><given-names>VM</given-names></name><name><surname>Williams</surname><given-names>MD</given-names></name><etal></etal></person-group>. <article-title>Treatment outcomes of depression: the pharmacogenomic research network antidepressant medication pharmacogenomic study</article-title>. <source/>J Clin Psychopharmacol. (<year>2014</year>) <volume>34</volume>:<fpage>313</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1097/JCP.0000000000000099</pub-id><pub-id pub-id-type="pmid">24743713</pub-id></mixed-citation>
</ref>
<ref id="B36">
<label>36.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Biernacka</surname><given-names>JM</given-names></name><name><surname>Sangkuhl</surname><given-names>K</given-names></name><name><surname>Jenkins</surname><given-names>G</given-names></name><name><surname>Whaley</surname><given-names>RM</given-names></name><name><surname>Barman</surname><given-names>P</given-names></name><name><surname>Batzler</surname><given-names>A</given-names></name><etal></etal></person-group>. <article-title>The international SSRI pharmacogenomics consortium (ISPC): a genome-wide association study of antidepressant treatment response</article-title>. <source/>Transl Psychiatr. (<year>2015</year>) <volume>5</volume>:<fpage>e553</fpage>. <pub-id pub-id-type="doi">10.1038/tp.2015.47</pub-id><pub-id pub-id-type="pmid">25897834</pub-id></mixed-citation>
</ref>
<ref id="B37">
<label>37.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Garriock</surname><given-names>HA</given-names></name><name><surname>Kraft</surname><given-names>JB</given-names></name><name><surname>Shyn</surname><given-names>SI</given-names></name><name><surname>Peters</surname><given-names>EJ</given-names></name><name><surname>Yokoyama</surname><given-names>JS</given-names></name><name><surname>Jenkins</surname><given-names>GD</given-names></name><etal></etal></person-group>. <article-title>A genomewide association study of citalopram response in major depressive disorder</article-title>. <source/>Biol Psychiatr. (<year>2010</year>) <volume>67</volume>:<fpage>133</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2009.08.029</pub-id><pub-id pub-id-type="pmid">19846067</pub-id></mixed-citation>
</ref>
<ref id="B38">
<label>38.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Uher</surname><given-names>R</given-names></name><name><surname>Perroud</surname><given-names>N</given-names></name><name><surname>Ng</surname><given-names>MY</given-names></name><name><surname>Hauser</surname><given-names>J</given-names></name><name><surname>Henigsberg</surname><given-names>N</given-names></name><name><surname>Maier</surname><given-names>W</given-names></name><etal></etal></person-group>. <article-title>Genome-wide pharmacogenetics of antidepressant response in the GENDEP project</article-title>. <source/>Am J Psychiatr. (<year>2010</year>) <volume>167</volume>:<fpage>555</fpage>–<lpage>64</lpage>. <pub-id pub-id-type="doi">10.1176/appi.ajp.2009.09070932</pub-id><pub-id pub-id-type="pmid">20360315</pub-id></mixed-citation>
</ref>
<ref id="B39">
<label>39.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ising</surname><given-names>M</given-names></name><name><surname>Lucae</surname><given-names>S</given-names></name><name><surname>Binder</surname><given-names>EB</given-names></name><name><surname>Bettecken</surname><given-names>T</given-names></name><name><surname>Uhr</surname><given-names>M</given-names></name><name><surname>Ripke</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>A genomewide association study points to multiple loci that predict antidepressant drug treatment outcome in depression</article-title>. <source/>Arch Gen Psychiatr. (<year>2009</year>) <volume>66</volume>:<fpage>966</fpage>–<lpage>975</lpage>. <pub-id pub-id-type="doi">10.1001/archgenpsychiatry.2009.95</pub-id><pub-id pub-id-type="pmid">19736353</pub-id></mixed-citation>
</ref>
<ref id="B40">
<label>40.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Laje</surname><given-names>G</given-names></name><name><surname>McMahon</surname><given-names>FJ</given-names></name></person-group>. <article-title>Genome-wide association studies of antidepressant outcome: a brief review</article-title>. <source/>Prog Neuropsychopharmacol Biol Psychiatr. (<year>2011</year>) <volume>35</volume>:<fpage>1553</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1016/j.pnpbp.2010.11.031</pub-id><pub-id pub-id-type="pmid">21115088</pub-id></mixed-citation>
</ref>
<ref id="B41">
<label>41.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Myung</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Lim</surname><given-names>SW</given-names></name><name><surname>Shim</surname><given-names>S</given-names></name><name><surname>Won</surname><given-names>HH</given-names></name><name><surname>Kim</surname><given-names>S</given-names></name><etal></etal></person-group>
<article-title>A genome-wide association study of antidepressant response in Koreans</article-title>. <source/>Transl Psychiatr. (<year>2015</year>) <volume>5</volume>:<fpage>e633</fpage>
<pub-id pub-id-type="doi">10.1038/tp.2015.127</pub-id></mixed-citation>
</ref>
<ref id="B42">
<label>42.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whirl-Carrillo</surname><given-names>M</given-names></name><name><surname>McDonagh</surname><given-names>EM</given-names></name><name><surname>Hebert</surname><given-names>JM</given-names></name><name><surname>Gong</surname><given-names>L</given-names></name><name><surname>Sangkuhl</surname><given-names>K</given-names></name><name><surname>Thorn</surname><given-names>CF</given-names></name><etal></etal></person-group>. <article-title>Pharmacogenomics knowledge for personalized medicine</article-title>. <source/>Clin Pharmacol Ther. (<year>2012</year>) <volume>92</volume>:<fpage>414</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1038/clpt.2012.96</pub-id><pub-id pub-id-type="pmid">22992668</pub-id></mixed-citation>
</ref>
<ref id="B43">
<label>43.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sim</surname><given-names>NL</given-names></name><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Henikoff</surname><given-names>S</given-names></name><name><surname>Schneider</surname><given-names>G</given-names></name><name><surname>Ng</surname><given-names>PC</given-names></name></person-group>. <article-title>SIFT web server: predicting effects of amino acid substitutions on proteins</article-title>. <source/>Nucleic Acids Res. (<year>2012</year>) <volume>40</volume>:<fpage>W452</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gks539</pub-id><pub-id pub-id-type="pmid">22689647</pub-id></mixed-citation>
</ref>
<ref id="B44">
<label>44.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adzhubei</surname><given-names>IA</given-names></name><name><surname>Schmidt</surname><given-names>S</given-names></name><name><surname>Peshkin</surname><given-names>L</given-names></name><name><surname>Ramensky</surname><given-names>VE</given-names></name><name><surname>Gerasimova</surname><given-names>A</given-names></name><name><surname>Bork</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>A method and server for predicting damaging missense mutations</article-title>. <source/>Nat Methods. (<year>2010</year>) <volume>7</volume>:<fpage>248</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1038/nmeth0410-248</pub-id><pub-id pub-id-type="pmid">20354512</pub-id></mixed-citation>
</ref>
<ref id="B45">
<label>45.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hecht</surname><given-names>M</given-names></name><name><surname>Bromberg</surname><given-names>Y</given-names></name><name><surname>Rost</surname><given-names>B</given-names></name></person-group>. <article-title>Better prediction of functional effects for sequence variants</article-title>. <source/>BMC Genomics. (<year>2015</year>) <volume>16</volume>:<fpage>S1</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2164-16-S8-S1</pub-id><pub-id pub-id-type="pmid">26110438</pub-id></mixed-citation>
</ref>
<ref id="B46">
<label>46.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Capriotti</surname><given-names>E</given-names></name><name><surname>Fariselli</surname><given-names>P</given-names></name><name><surname>Casadio</surname><given-names>R</given-names></name></person-group>
<article-title>I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure</article-title>. <source/>Nucleic Acids Res. (<year>2005</year>) <volume>33</volume>:<fpage>W306</fpage>–<lpage>10</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gki375</pub-id><pub-id pub-id-type="pmid">15980478</pub-id></mixed-citation>
</ref>
<ref id="B47">
<label>47.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ashkenazy</surname><given-names>H</given-names></name><name><surname>Abadi</surname><given-names>S</given-names></name><name><surname>Martz</surname><given-names>E</given-names></name><name><surname>Chay</surname><given-names>O</given-names></name><name><surname>Mayrose</surname><given-names>I</given-names></name><name><surname>Pupko</surname><given-names>T</given-names></name><etal></etal></person-group>. <article-title>ConSurf 2016: an improved methodology to estimate and visualize evolutionary conservation in macromolecules</article-title>. <source/>Nucleic Acids Res. (<year>2016</year>) <volume>44</volume>:<fpage>W344</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gkw408</pub-id><pub-id pub-id-type="pmid">27166375</pub-id></mixed-citation>
</ref>
<ref id="B48">
<label>48.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Waterhouse</surname><given-names>A</given-names></name><name><surname>Bertoni</surname><given-names>M</given-names></name><name><surname>Bienert</surname><given-names>S</given-names></name><name><surname>Studer</surname><given-names>G</given-names></name><name><surname>Tauriello</surname><given-names>G</given-names></name><name><surname>Gumienny</surname><given-names>R</given-names></name><etal></etal></person-group>. <article-title>SWISS-MODEL: homology modelling of protein structures and complexes</article-title>. <source/>Nucleic Acids Res. (<year>2018</year>) <volume>46</volume>:<fpage>W296</fpage>–<lpage>303</lpage>. <pub-id pub-id-type="doi">10.1093/nar/gky427</pub-id><pub-id pub-id-type="pmid">29788355</pub-id></mixed-citation>
</ref>
<ref id="B49">
<label>49.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abraham</surname><given-names>MJ</given-names></name><name><surname>Murtola</surname><given-names>TJ</given-names></name><name><surname>Schulz</surname><given-names>R</given-names></name><name><surname>Páll</surname><given-names>S</given-names></name><name><surname>Smith</surname><given-names>JC</given-names></name><name><surname>Hess</surname><given-names>B</given-names></name><etal></etal></person-group>
<article-title>GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers</article-title>. <source/>SoftwareX. (<year>2015</year>) 1–<volume>2</volume>:<fpage>19</fpage>–<lpage>25</lpage>. <pub-id pub-id-type="doi">10.1016/j.softx.2015.06.001</pub-id></mixed-citation>
</ref>
<ref id="B50">
<label>50.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lindorff-Larsen</surname><given-names>K</given-names></name><name><surname>Piana</surname><given-names>S</given-names></name><name><surname>Palmo</surname><given-names>K</given-names></name><name><surname>Maragakis</surname><given-names>P</given-names></name><name><surname>Klepeis</surname><given-names>JL</given-names></name><name><surname>Dror</surname><given-names>RO</given-names></name><etal></etal></person-group>. <article-title>Improved side-chain torsion potentials for the Amber ff99SB protein force field</article-title>. <source/>Proteins. (<year>2010</year>) <volume>78</volume>:<fpage>1950</fpage>–<lpage>8</lpage>. <pub-id pub-id-type="doi">10.1002/prot.22711</pub-id><pub-id pub-id-type="pmid">20408171</pub-id></mixed-citation>
</ref>
<ref id="B51">
<label>51.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>A</given-names></name><name><surname>Savas</surname><given-names>U</given-names></name><name><surname>Hsu</surname><given-names>MH</given-names></name><name><surname>Stout</surname><given-names>CD</given-names></name><name><surname>Johnson</surname><given-names>EF</given-names></name></person-group>. <article-title>Crystal structure of human cytochrome P450 2D6 with prinomastat bound</article-title>. <source/>J Biol Chem. (<year>2012</year>) <volume>287</volume>:<fpage>10834</fpage>–<lpage>43</lpage>. <pub-id pub-id-type="doi">10.1074/jbc.M111.307918</pub-id><pub-id pub-id-type="pmid">22308038</pub-id></mixed-citation>
</ref>
<ref id="B52">
<label>52.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fujikura</surname><given-names>K</given-names></name><name><surname>Ingelman-Sundberg</surname><given-names>M</given-names></name><name><surname>Lauschke</surname><given-names>VM</given-names></name></person-group>. <article-title>Genetic variation in the human cytochrome P450 supergene family</article-title>. <source/>Pharmacogenet Genomics. (<year>2015</year>) <volume>25</volume>:<fpage>584</fpage>–<lpage>94</lpage>. <pub-id pub-id-type="doi">10.1097/FPC.0000000000000172</pub-id><pub-id pub-id-type="pmid">26340336</pub-id></mixed-citation>
</ref>
<ref id="B53">
<label>53.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maréchal</surname><given-names>JD</given-names></name><name><surname>Kemp</surname><given-names>CA</given-names></name><name><surname>Roberts</surname><given-names>GC</given-names></name><name><surname>Paine</surname><given-names>MJ</given-names></name><name><surname>Wolf</surname><given-names>CR</given-names></name><name><surname>Sutcliffe</surname><given-names>MJ</given-names></name></person-group>. <article-title>Insights into drug metabolism by cytochromes P450 from modelling studies of CYP2D6-drug interactions</article-title>. <source/>Br J Pharmacol. (<year>2008</year>) <volume>153</volume>(<issue>Suppl. 1</issue>):S82–9. <pub-id pub-id-type="doi">10.1038/sj.bjp.0707570</pub-id><pub-id pub-id-type="pmid">18026129</pub-id></mixed-citation>
</ref>
<ref id="B54">
<label>54.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhou</surname><given-names>SF</given-names></name></person-group>. <article-title>Polymorphism of human cytochrome P450 2D6its clinical significance: part II</article-title>. <source/>Clin Pharmacokinet. (<year>2009</year>) <volume>48</volume>:<fpage>761</fpage>–<lpage>804</lpage>. <pub-id pub-id-type="doi">10.2165/11318070-000000000-00000</pub-id><pub-id pub-id-type="pmid">19902987</pub-id></mixed-citation>
</ref>
<ref id="B55">
<label>55.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ng</surname><given-names>C</given-names></name><name><surname>Sarris</surname><given-names>J</given-names></name><name><surname>Singh</surname><given-names>A</given-names></name><name><surname>Bousman</surname><given-names>C</given-names></name><name><surname>Byron</surname><given-names>K</given-names></name><name><surname>Peh</surname><given-names>LH</given-names></name><etal></etal></person-group>. <article-title>Pharmacogenetic polymorphisms and response to escitalopram and venlafaxine over 8 weeks in major depression</article-title>. <source/>Hum Psychopharmacol. (<year>2013</year>) <volume>28</volume>:<fpage>516</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1002/hup.2340</pub-id><pub-id pub-id-type="pmid">24014145</pub-id></mixed-citation>
</ref>
<ref id="B56">
<label>56.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hodgson</surname><given-names>K</given-names></name><name><surname>Tansey</surname><given-names>K</given-names></name><name><surname>Dernovsek</surname><given-names>MZ</given-names></name><name><surname>Hauser</surname><given-names>J</given-names></name><name><surname>Henigsberg</surname><given-names>N</given-names></name><name><surname>Maier</surname><given-names>W</given-names></name><etal></etal></person-group>. <article-title>Genetic differences in cytochrome P450 enzymes and antidepressant treatment response</article-title>. <source/>J Psychopharmacol. (<year>2014</year>) <volume>28</volume>:<fpage>133</fpage>–<lpage>41</lpage>. <pub-id pub-id-type="doi">10.1177/0269881113512041</pub-id><pub-id pub-id-type="pmid">24257813</pub-id></mixed-citation>
</ref>
<ref id="B57">
<label>57.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Taranu</surname><given-names>A</given-names></name><name><surname>Colle</surname><given-names>R</given-names></name><name><surname>Gressier</surname><given-names>F</given-names></name><name><surname>El Asmar</surname><given-names>K</given-names></name><name><surname>Becquemont</surname><given-names>L</given-names></name><name><surname>Corruble</surname><given-names>E</given-names></name><etal></etal></person-group>. <article-title>Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?</article-title>
<source/>Pharmacogenomics. (<year>2017</year>) <volume>18</volume>:<fpage>639</fpage>–<lpage>50</lpage>. <pub-id pub-id-type="doi">10.2217/pgs-2017-0003</pub-id><pub-id pub-id-type="pmid">28480819</pub-id></mixed-citation>
</ref>
<ref id="B58">
<label>58.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Torrellas</surname><given-names>C</given-names></name><name><surname>Carril</surname><given-names>JC</given-names></name><name><surname>Cacabelos</surname><given-names>R</given-names></name></person-group>. <article-title>Optimization of antidepressant use with pharmacogenetic strategies</article-title>. <source/>Curr Genomics. (<year>2017</year>) <volume>18</volume>:<fpage>442</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.2174/1389202918666170426164940</pub-id><pub-id pub-id-type="pmid">29081699</pub-id></mixed-citation>
</ref>
<ref id="B59">
<label>59.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zastrozhin</surname><given-names>MS</given-names></name><name><surname>Grishina</surname><given-names>EA</given-names></name><name><surname>Denisenko</surname><given-names>NP</given-names></name><name><surname>Skryabin</surname><given-names>VY</given-names></name><name><surname>Markov</surname><given-names>DD</given-names></name><name><surname>Savchenko</surname><given-names>LM</given-names></name><etal></etal></person-group>. <article-title>Effects of CYP2D6 genetic polymorphisms on the efficacy and safety of fluvoxamine in patients with depressive disorder and comorbid alcohol use disorder</article-title>. <source/>Pharmacogenomics Pers Med. (<year>2018</year>) <volume>11</volume>:<fpage>113</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.2147/PGPM.S160763</pub-id><pub-id pub-id-type="pmid">29988737</pub-id></mixed-citation>
</ref>
<ref id="B60">
<label>60.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>MH</given-names></name><name><surname>Lin</surname><given-names>KM</given-names></name><name><surname>Hsiao</surname><given-names>MC</given-names></name><name><surname>Shen</surname><given-names>WW</given-names></name><name><surname>Lu</surname><given-names>ML</given-names></name><name><surname>Tang</surname><given-names>HS</given-names></name><etal></etal></person-group>. <article-title>Genetic polymorphisms of cytochrome P450 enzymes influence metabolism of the antidepressant escitalopram and treatment response</article-title>. <source/>Pharmacogenomics. (<year>2010</year>) <volume>11</volume>:<fpage>537</fpage>–<lpage>46</lpage>. <pub-id pub-id-type="doi">10.2217/pgs.09.168</pub-id><pub-id pub-id-type="pmid">20350136</pub-id></mixed-citation>
</ref>
<ref id="B61">
<label>61.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Han</surname><given-names>KM</given-names></name><name><surname>Chang</surname><given-names>HS</given-names></name><name><surname>Choi</surname><given-names>IK</given-names></name><name><surname>Ham</surname><given-names>BJ</given-names></name><name><surname>Lee</surname><given-names>MS</given-names></name></person-group>. <article-title>CYP2D6 P34S polymorphism and outcomes of escitalopram treatment in Koreans with major depression</article-title>. <source/>Psychiatry Invest. (<year>2013</year>) <volume>10</volume>:<fpage>286</fpage>–<lpage>93</lpage>. <pub-id pub-id-type="doi">10.4306/pi.2013.10.3.286</pub-id><pub-id pub-id-type="pmid">24302953</pub-id></mixed-citation>
</ref>
<ref id="B62">
<label>62.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Venselaar</surname><given-names>H</given-names></name><name><surname>Te Beek</surname><given-names>TA</given-names></name><name><surname>Kuipers</surname><given-names>RK</given-names></name><name><surname>Hekkelman</surname><given-names>ML</given-names></name><name><surname>Vriend</surname><given-names>G</given-names></name></person-group>. <article-title>Protein structure analysis of mutations causing inheritable diseases. An e-Science approach with life scientist friendly interfaces</article-title>. <source/>BMC Bioinformatics. (<year>2010</year>) <volume>11</volume>:<fpage>548</fpage>. <pub-id pub-id-type="doi">10.1186/1471-2105-11-548</pub-id><pub-id pub-id-type="pmid">21059217</pub-id></mixed-citation>
</ref>
<ref id="B63">
<label>63.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>AN</given-names></name><name><surname>Ahemad</surname><given-names>N</given-names></name><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Palanisamy</surname><given-names>UD</given-names></name><name><surname>Yiap</surname><given-names>BC</given-names></name><name><surname>Ong</surname><given-names>CE</given-names></name></person-group>. <article-title>Functional and structural characterisation of common cytochrome P450 2D6 allelic variants-roles of Pro34 and Thr107 in catalysis and inhibition</article-title>. <source/>Naunyn Schmiedebergs Arch Pharmacol. (<year>2019</year>) <volume>392</volume>:<fpage>1015</fpage>–<lpage>29</lpage>. <pub-id pub-id-type="doi">10.1007/s00210-019-01651-0</pub-id><pub-id pub-id-type="pmid">31025144</pub-id></mixed-citation>
</ref>
<ref id="B64">
<label>64.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fukuyoshi</surname><given-names>S</given-names></name><name><surname>Kometani</surname><given-names>M</given-names></name><name><surname>Watanabe</surname><given-names>Y</given-names></name><name><surname>Hiratsuka</surname><given-names>M</given-names></name><name><surname>Yamaotsu</surname><given-names>N</given-names></name><name><surname>Hirono</surname><given-names>S</given-names></name><etal></etal></person-group>. <article-title>Molecular dynamics simulations to investigate the influences of amino acid mutations on protein three-dimensional structures of cytochrome P450 2D6.1, 2, 10, 14A, 51, and 62</article-title>. <source/>PLoS ONE. (<year>2016</year>) <volume>11</volume>:<fpage>e0152946</fpage>. <pub-id pub-id-type="doi">10.1371/journal.pone.0152946</pub-id><pub-id pub-id-type="pmid">27046024</pub-id></mixed-citation>
</ref>
<ref id="B65">
<label>65.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sakuyama</surname><given-names>K</given-names></name><name><surname>Sasaki</surname><given-names>T</given-names></name><name><surname>Ujiie</surname><given-names>S</given-names></name><name><surname>Obata</surname><given-names>K</given-names></name><name><surname>Mizugaki</surname><given-names>M</given-names></name><name><surname>Ishikawa</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Functional characterization of 17 CYP2D6 allelic variants (CYP2D6.2, 10, 14A-B, 18, 27, 36, 39, 47-51, 53-55, and 57)</article-title>. <source/>Drug Metab Dispos. (<year>2008</year>) <volume>36</volume>:<fpage>2460</fpage>–<lpage>7</lpage>. <pub-id pub-id-type="doi">10.1124/dmd.108.023242</pub-id><pub-id pub-id-type="pmid">18784265</pub-id></mixed-citation>
</ref>
<ref id="B66">
<label>66.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gaedigk</surname><given-names>A</given-names></name><name><surname>Bradford</surname><given-names>LD</given-names></name><name><surname>Alander</surname><given-names>SW</given-names></name><name><surname>Leeder</surname><given-names>JS</given-names></name></person-group>. <article-title>CYP2D6<sup>*</sup>36 gene arrangements within the cyp2d6 locus: association of CYP2D6<sup>*</sup>36 with poor metabolizer status</article-title>. <source/>Drug Metab Dispos. (<year>2006</year>) <volume>34</volume>:<fpage>563</fpage>–<lpage>9</lpage>. <pub-id pub-id-type="doi">10.1124/dmd.105.008292</pub-id><pub-id pub-id-type="pmid">16415111</pub-id></mixed-citation>
</ref>
<ref id="B67">
<label>67.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matsunaga</surname><given-names>M</given-names></name><name><surname>Yamazaki</surname><given-names>H</given-names></name><name><surname>Kiyotani</surname><given-names>K</given-names></name><name><surname>Iwano</surname><given-names>S</given-names></name><name><surname>Saruwatari</surname><given-names>J</given-names></name><name><surname>Nakagawa</surname><given-names>K</given-names></name><etal></etal></person-group>. <article-title>Two novel CYP2D6<sup>*</sup>10 haplotypes as possible causes of a poor metabolic phenotype in Japanese</article-title>. <source/>Drug Metab Dispos. (<year>2009</year>) <volume>37</volume>:<fpage>699</fpage>–<lpage>701</lpage>. <pub-id pub-id-type="doi">10.1124/dmd.108.026096</pub-id><pub-id pub-id-type="pmid">19158312</pub-id></mixed-citation>
</ref>
<ref id="B68">
<label>68.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Muroi</surname><given-names>Y</given-names></name><name><surname>Saito</surname><given-names>T</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Sakuyama</surname><given-names>K</given-names></name><name><surname>Niinuma</surname><given-names>Y</given-names></name><name><surname>Ito</surname><given-names>M</given-names></name><etal></etal></person-group>. <article-title>Functional characterization of wild-type and 49 CYP2D6 allelic variants for N-desmethyltamoxifen 4-hydroxylation activity</article-title>. <source/>Drug Metab Pharmacokinet. (<year>2014</year>) <volume>29</volume>:<fpage>360</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.2133/dmpk.DMPK-14-RG-014</pub-id><pub-id pub-id-type="pmid">24647041</pub-id></mixed-citation>
</ref>
<ref id="B69">
<label>69.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Lim</surname><given-names>YR</given-names></name><name><surname>Han</surname><given-names>S</given-names></name><name><surname>Han</surname><given-names>JS</given-names></name><name><surname>Chun</surname><given-names>YJ</given-names></name><name><surname>Yun</surname><given-names>CH</given-names></name><etal></etal></person-group>. <article-title>Functional influence of human CYP2D6 allelic variations: P34S, E418K, S486T,R296C</article-title>. <source/>Arch Pharm Res. (<year>2013</year>) <volume>36</volume>:<fpage>1500</fpage>–<lpage>6</lpage>. <pub-id pub-id-type="doi">10.1007/s12272-013-0212-5</pub-id><pub-id pub-id-type="pmid">23897164</pub-id></mixed-citation>
</ref>
<ref id="B70">
<label>70.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pu</surname><given-names>M</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Xu</surname><given-names>Z</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Geng</surname><given-names>L</given-names></name><name><surname>Yuan</surname><given-names>Y</given-names></name><etal></etal></person-group>. <article-title>Influence of genetic polymorphisms in the glutamatergic and GABAergic systems and their interactions with environmental stressors on antidepressant response</article-title>. <source/>Pharmacogenomics. (<year>2013</year>) <volume>14</volume>:<fpage>277</fpage>–<lpage>88</lpage>. <pub-id pub-id-type="doi">10.2217/pgs.13.1</pub-id><pub-id pub-id-type="pmid">23394390</pub-id></mixed-citation>
</ref>
<ref id="B71">
<label>71.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whiting</surname><given-names>PJ</given-names></name><name><surname>Bonnert</surname><given-names>TP</given-names></name><name><surname>McKernan</surname><given-names>RM</given-names></name><name><surname>Farrar</surname><given-names>S</given-names></name><name><surname>Le</surname><given-names>Bourdellès B</given-names></name><name><surname>Heavens</surname><given-names>RP</given-names></name><etal></etal></person-group>. <article-title>Molecular and functional diversity of the expanding GABA-A receptor gene family</article-title>. <source/>Ann N Y Acad Sci. (<year>1999</year>) <volume>868</volume>:<fpage>645</fpage>–<lpage>53</lpage>. <pub-id pub-id-type="doi">10.1111/j.1749-6632.1999.tb11341.x</pub-id><pub-id pub-id-type="pmid">10414349</pub-id></mixed-citation>
</ref>
<ref id="B72">
<label>72.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maciukiewicz</surname><given-names>M</given-names></name><name><surname>Marshe</surname><given-names>VS</given-names></name><name><surname>Tiwari</surname><given-names>AK</given-names></name><name><surname>Fonseka</surname><given-names>TM</given-names></name><name><surname>Freeman</surname><given-names>N</given-names></name><name><surname>Kennedy</surname><given-names>JL</given-names></name><etal></etal></person-group>. <article-title>Genome-wide association studies of placebo and duloxetine response in major depressive disorder</article-title>. <source/>Pharmacogenomics J. (<year>2018</year>) <volume>18</volume>:<fpage>406</fpage>–<lpage>12</lpage>. <pub-id pub-id-type="doi">10.1038/tpj.2017.29</pub-id><pub-id pub-id-type="pmid">28696415</pub-id></mixed-citation>
</ref>
<ref id="B73">
<label>73.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkie</surname><given-names>MJ</given-names></name><name><surname>Smith</surname><given-names>G</given-names></name><name><surname>Day</surname><given-names>RK</given-names></name><name><surname>Matthews</surname><given-names>K</given-names></name><name><surname>Smith</surname><given-names>D</given-names></name><name><surname>Blackwood</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>Polymorphisms in the SLC6A4 and HTR2A genes influence treatment outcome following antidepressant therapy</article-title>. <source/>Pharmacogenomics J. (<year>2009</year>) <volume>9</volume>:<fpage>61</fpage>–<lpage>70</lpage>. <pub-id pub-id-type="doi">10.1038/sj.tpj.6500491</pub-id><pub-id pub-id-type="pmid">18253134</pub-id></mixed-citation>
</ref>
<ref id="B74">
<label>74.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Minov</surname><given-names>C</given-names></name><name><surname>Baghai</surname><given-names>TC</given-names></name><name><surname>Schüle</surname><given-names>C</given-names></name><name><surname>Zwanzger</surname><given-names>P</given-names></name><name><surname>Schwarz</surname><given-names>MJ</given-names></name><name><surname>Zill</surname><given-names>P</given-names></name><etal></etal></person-group>. <article-title>Serotonin-2A-receptor and -transporter polymorphisms: lack of association in patients with major depression</article-title>. <source/>Neurosci Lett. (<year>2001</year>) <volume>303</volume>:<fpage>119</fpage>–<lpage>22</lpage>. <pub-id pub-id-type="doi">10.1016/S0304-3940(01)01704-9</pub-id><pub-id pub-id-type="pmid">11311507</pub-id></mixed-citation>
</ref>
<ref id="B75">
<label>75.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Smith</surname><given-names>RM</given-names></name><name><surname>Papp</surname><given-names>AC</given-names></name><name><surname>Webb</surname><given-names>A</given-names></name><name><surname>Ruble</surname><given-names>CL</given-names></name><name><surname>Munsie</surname><given-names>LM</given-names></name><name><surname>Nisenbaum</surname><given-names>LK</given-names></name><etal></etal></person-group>. <article-title>Multiple regulatory variants modulate expression of 5-hydroxytryptamine 2A receptors in human cortex</article-title>. <source/>Biol Psychiatry. (<year>2013</year>) <volume>73</volume>:<fpage>546</fpage>–<lpage>54</lpage>. <pub-id pub-id-type="doi">10.1016/j.biopsych.2012.09.028</pub-id><pub-id pub-id-type="pmid">23158458</pub-id></mixed-citation>
</ref>
<ref id="B76">
<label>76.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMahon</surname><given-names>FJ</given-names></name><name><surname>Buervenich</surname><given-names>S</given-names></name><name><surname>Charney</surname><given-names>D</given-names></name><name><surname>Lipsky</surname><given-names>R</given-names></name><name><surname>Rush</surname><given-names>AJ</given-names></name><name><surname>Wilson</surname><given-names>AF</given-names></name><etal></etal></person-group>. <article-title>Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment</article-title>. <source/>Am J Hum Genet. (<year>2006</year>) <volume>78</volume>:<fpage>804</fpage>–<lpage>14</lpage>. <pub-id pub-id-type="doi">10.1086/503820</pub-id><pub-id pub-id-type="pmid">16642436</pub-id></mixed-citation>
</ref>
<ref id="B77">
<label>77.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Horstmann</surname><given-names>S</given-names></name><name><surname>Lucae</surname><given-names>S</given-names></name><name><surname>Menke</surname><given-names>A</given-names></name><name><surname>Hennings</surname><given-names>JM</given-names></name><name><surname>Ising</surname><given-names>M</given-names></name><name><surname>Roeske</surname><given-names>D</given-names></name><etal></etal></person-group>. <article-title>Polymorphisms in GRIK4, HTR2A, and FKBP5 show interactive effects in predicting remission to antidepressant treatment</article-title>. <source/>Neuropsychopharmacology. (<year>2010</year>) <volume>35</volume>:<fpage>727</fpage>–<lpage>40</lpage>. <pub-id pub-id-type="doi">10.1038/npp.2009.180</pub-id><pub-id pub-id-type="pmid">19924111</pub-id></mixed-citation>
</ref>
<ref id="B78">
<label>78.</label>
<mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>EJ</given-names></name><name><surname>Reichardt</surname><given-names>LF</given-names></name></person-group>. <article-title>Neurotrophins: roles in neuronal development and function</article-title>. <source/>Annu Rev Neurosci. (<year>2001</year>) <volume>24</volume>:<fpage>677</fpage>–<lpage>736</lpage>. <pub-id pub-id-type="doi">10.1146/annurev.neuro.24.1.677</pub-id>
<pub-id pub-id-type="pmid">11520916</pub-id></mixed-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>